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Yi-Chun Chen 
 
STRESS-INDUCIBLE MIG6 PROMOTES PANCREATIC BETA CELL 
DESTRUCTION IN THE PATHOGENESIS OF DIABETES 
 
Pancreatic insulin-secreting beta cell failure is central to the development of 
diabetes.  Therapeutic applications targeted at understanding and manipulating beta cell 
destruction mechanisms should enhance the preservation of functional beta cell mass and 
prevent diabetes.  To this end, we have demonstrated that diabetogenic assaults (e.g., 
endoplasmic reticulum stress, glucolipotoxicity, and pro-inflammatory cytokines) 
attenuate the activation of beta cell pro-survival signaling pathways via a stress-inducible 
molecule called Mitogen-inducible gene 6 (Mig6).  We discovered that the 
overabundance of Mig6 exacerbates stress-induced beta cell apoptosis and inhibits insulin 
secretion.  Conversely, the deficiency of Mig6 partially protected beta cells from DNA 
damage-induced cell death.  Further, we established that Mig6 haploinsufficient mice 
retained islet integrity and function and exhibited greater beta cell mass recovery 
following treatment with multiple low doses of the beta cell toxin streptozotocin.  These 
data suggest that Mig6 may be a therapeutic target for beta cell preservation in diabetes. 
 
 
 
Patrick T. Fueger, Ph.D., Chair 
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1 INTRODUCTION 
1.1 Type 1 diabetes 
1.1.1 Epidemiology and diagnosis 
Diabetes mellitus is one of the most common non-communicable diseases, 
affecting more than 366 million people worldwide.  By 2030, the prevalence of diabetes 
is predicted to rise to a staggering 552 million (1).  There are two type of diabetes – type 
1 and type 2 diabetes (T1D and T2D, respectively).  T1D, classified by the presence of 
autoimmune-mediated beta cell destruction (2), accounts for approximately 5% of 
diabetes mellitus patients.  
Historically, T1D has been considered a child- or juvenile-onset disease; however, 
age is not the defining factor.  The main symptoms of T1D are polyuria, polydipsia, and 
polyphagia, and the clinical features are hyperglycemia, weight loss, and diabetic 
ketoacidosis.  The diagnostic criteria include: a random plasma glucose concentration 
≥ 11.1 mmol/L or a fasting plasma glucose concentration ≥ 7.0 mmol/L (3).  Other 
diagnostic markers such as plasma autoantibody levels, C-peptide levels, and ketonuria 
are currently not recommended for routine diagnostic use (4-6). 
1.1.2 Etiology of T1D 
Most of our understanding about the pathogenesis of T1D comes from: 1) 
retrospective patients’ serum samples and cadaveric pancreata analyses, and 2) T1D 
prevention or intervention trials.  These studies demonstrate that T1D is an autoimmune-
mediated disease, in which pancreatic beta cells are destroyed, resulting in insulin 
deficiency and hyperglycemia.  The proposed causes of T1D include genetic 
predisposition and environmental factors.   
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Genetic predisposition is required for the development of T1D (7).  Whereas early 
twin studies suggested that the risk of T1D for the monozygotic twins of patients with 
T1D is as low as 30%, a recent cumulative incidence analysis revealed that the 
concordance of twins exceeds 65% by age 60 (8), indicating strong genetic basis for T1D.  
The linkage and candidate gene studies, and recent genome-wide association study 
(GWAS) have revealed more than 50 loci associated with risk to T1D.  Among them, 
human leukocyte antigen (HLA) class II DR and DQ alleles show the greatest risk (7, 9).  
HLA alleles encode a group of surface proteins that present antigen to T lymphocytes, 
and thus alterations in HLA alleles may modulate antigen epitope presentation (10), 
leading to disrupted central tolerance and autoimmune reactions (11-13).  The second 
prominent T1D risk loci is located upstream of the insulin gene (INS, encoding pre-
proinsulin peptide).  The length of the variable number tandem repeats (VNTR) in that 
loci controls the thymic INS expression level, therefore regulating the immune tolerance 
toward insulin (14-16).  Other frequent T1D risk loci are PTPN22 (encoding lymphoid 
protein tyrosine phosphatase, a suppressor of T cell activation) (17, 18), IL2RA (α-
subunit of the IL-2 receptor, which controls self-tolerance) (19), and CTLA4 (T-cell-
specific transmembrane co-receptor, negative regulator of T cell activation).  The 
extensive collection of genetic studies highlight the immunological origin of T1D, that is, 
an incomplete self-tolerance to beta cell antigens triggers an adaptive immune response, 
disrupts innate immunity, and results in the destruction of beta cells.   However, further 
genetic mapping and functional studies must be performed to gain a better understanding 
of the molecular mechanisms leading to the development of T1D. 
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Despite the influence of genetic susceptibility, the etiology of T1D cannot be fully 
explained by genetics because: 1) the pair-wise concordance of T1D in monozygotic 
twins is lower than expected if T1D was purely due to genetics (8), and the disease 
progression rates vary (20), 2) the proportion of subjects with high-risk HLA genotypes 
has decreased in the last few decades, whereas the low-risk HLA population has 
increased (21, 22), suggesting genetic predisposition’s contribution to T1D is decreasing 
(23), 3) the T1D geographical distribution pattern (highly concentrated in Northern 
Europe) cannot solely be explained by genetic factors (24), and 4) migration studies 
suggest that the population from low incidence regions have increased T1D frequency 
when they move to high incidence regions (25), highlighting the environmental 
influences on T1D etiology.  Although the identification of environmental factors is still 
in its early stages, viruses (26), bacteria (27), and diet (20) have been suggested to trigger 
and/or potentiate the development of T1D.   
1.1.3 The natural history of T1D  
In 1986, Dr. George Eisenbarth first proposed that T1D is a cell-mediated 
autoimmune disease (28).  In his well-received T1D pathogenesis model, the natural 
history of T1D could be separated into different stages as illustrated in Figure 1-1.    
First, genetic and environmental factors trigger the autoimmune response.  
Subsequently, the dysregulated immune system attacks pancreatic beta cells, leading to 
beta cell de-granulation and death.   In this stage, the surviving beta cells are still able to 
produce sufficient insulin to meet the body’s metabolic demands.  Only when a critical 
amount of functional beta cells are destroyed, do the clinical symptoms (e.g., 
hyperglycemia and glucose intolerance) emerge and T1D is diagnosed.   
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Following diagnosis and the initiation of insulin therapy, most patients experience 
a transient period of beta cell recovery (known as the “honeymoon phase”).  Ultimately 
though, most beta cells succumb to death after the disease onset.  However, in some 
longstanding patients, low concentrations of C-peptide and scant numbers of beta cells 
are observed (29).   
 
Figure 1-1   
 
The natural history of T1D (Modified from Akirav et al. (30) and Von Herrath et al. 
(31)). 
 
 
The already complex model for the natural history of T1D will undoubtedly 
become even more complex in the future.  As new technology has emerged leading to 
additional discoveries, we are now starting to appreciate the complex cellular and 
molecular events of immune-mediated beta cell destruction in both the preclinical and 
clinical stages of T1D.  Importantly, the prodrome stage of T1D may last from months to 
decades (32).  The implications of this timeframe are that the therapeutic window to 
prevent the onset of T1D is much longer than what was originally thought decades ago. 
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Pre-clinical stage: 
Immune-mediated attack 
Physiological beta cell injury or basal beta cell turnover/death are speculated to 
initiate homing of macrophages and dendritic cells (33).  Infiltrated macrophages 
normally secrete chemokines and pro-inflammatory cytokines (such as interleukin-1 beta 
and tumor necrosis factor alpha) to attract dendritic cells and T cells.  Yet under normal 
conditions, the antigen presenting cells do not present autoantigens to T cells, nor should 
the recruited T cells become active (34-36).  However, T cells with high-affinity T cell 
receptors for self-peptide-MHC complexes escaping the selection by thymus or 
peripheral deletion can become autoreactive and attack the beta cells.  Intriguingly, many 
studies suggest that islet inflammation is rarely observed in pre-onset (and even recently-
onset) individuals, suggesting T1D to be a heterogeneous disease driven by extra-
immunological causes (37-39).  Unquestionably, compared to the non-obese diabetic 
mouse model (NOD, a spontaneous model of T1D), pre-onset humans often have less 
frequent infiltrating immune cells (mainly CD3+/CD8+ T cells, CD68+ macrophages, with 
few CD20+ B cells and CD3+/CD4+ T cells (38)) and develop diabetes more slowly.  
However, extrapolating data/conclusions based on limited pre-onset cadaveric samples 
should to be interpreted with great caution.  If more pancreas samples from pre-diabetic 
donors become available, it is very likely that more lymphocyte species will be identified 
and characterized (40).  Additionally, in the near future, once the time-to-onset prediction 
substantially improves, more knowledge of how cell-mediated immunity contributes to 
T1D will be attained.  
 	   21	  
Apart	  from	  cell-­‐mediated	  immunity,	  humoral	  immunity	  is	  also	  associated	  with	  the	  etiology	  of	  T1D	  (41).	  	  In	  humans,	  the	  presence	  of	  islet	  autoantibodies	  is	  the	  earliest	  indicator	  of	  pre-­‐diabetes,	  and	  there	  is	  a	  strong	  association	  between	  the	  presence	  of	  multiple	  antibodies	  and	  the	  risk	  of	  developing	  T1D	  (42-­‐44).	  	  However,	  the	  autoantibodies	  are	  considered	  by-­‐products	  of	  B	  cell	  activation	  and	  therefore	  perceived	  as	  non-­‐pathogenic	  (45-­‐47).	  	  The	  primary	  way	  in	  which	  B	  cells	  contribute	  to	  T1D	  seems	  to	  be	  through	  their	  antigen	  presentation	  function	  (48).	  	  	  To	  date,	  multiple	  T1D	  autoantigens	  have	  been	  identified,	  including	  those	  targeting	  insulin	  (49,	  50),	  proinsulin	  (51,	  52),	  glutamate	  decarboxylase	  (GAD65)	  (53,	  54),	  islet-­‐specific	  glucose-­‐6-­‐phosphatase	  catalytic	  subunit-­‐related	  protein	  (IGRP)	  (55),	  insulinoma-­‐associated	  antigen	  2	  (IA2),	  and	  Zinc	  transporter	  8	  (ZNT8)	  (56).	  	  Interestingly,	  as	  the	  majority	  of	  identified	  targets	  of	  beta	  cell	  autoantigens	  traffic	  through	  the	  endoplasmic	  reticulum	  (ER)	  and	  become	  localized	  within	  the	  secretory	  granules,	  ER	  abnormalities	  are	  suspected	  to	  contribute	  to	  autoantigenicity	  (57,	  58).	  	  Indeed,	  recent	  reports	  have	  demonstrated	  that	  multiple	  ER	  stress	  markers	  are	  elevated	  before	  the	  onset	  of	  T1D	  in	  rodent	  models	  (59,	  60).	  	  It	  will	  be	  important	  to	  determine:	  1)	  if	  the	  misfolded	  proteins	  become	  neo-­‐antigens,	  2)	  if	  the	  upregulation	  of	  the	  ER-­‐associated	  degradation	  (ERAD)	  pathway	  allows	  autoreactive	  cells	  to	  escape	  the	  unfolded	  protein	  response	  (UPR)-­‐mediated	  beta	  cell	  death,	  thus	  facilitating	  T1D	  pathogenesis	  (37,	  58),	  and	  3)	  whether	  ER	  stress	  in	  beta	  cells	  precipitates	  immunopathy	  of	  T1D	  in	  humans.	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Beta cell turnover	  
As autoimmune-mediated beta cell destruction proceeds, the exposure of new 
autoantigens (either released from damaged beta cells or derived from dysregulated 
secretory pathways) may further precipitate the adaptive immune response and augment 
the killing of remaining beta cells (61).  On the other hand, compensatory beta cell 
growth may already exist in autoantibody-positive subjects.  The histopathological 
observations have demonstrated the presence of: 1) small- and medium-sized islets, 2) 
neogenesis of endocrine cells within the ductal epithelium, and 3) Ki67+ beta cells in the 
pancreas from pre-clinical individuals (39).  Indeed, although the overall beta cell loss is 
linear during the progression of T1D, at any given time, the heterogeneous beta cells may 
differentially respond to the inflammatory microenvironment and metabolic demands.  
As such, the cellular regeneration or death programs are triggered according to the 
integrated cellular intrinsic and extrinsic signals (62).   
Beta cell (dys)function 
Regarding beta cell function, preclinical T1D subjects usually develop a reduced 
first-phase insulin response (FPIR) immediately after their seroconversion (e.g., when the 
first T1D autoantibody is detectable in the blood) (63, 64).  Therefore, the reduced FPIR, 
along with the presence of autoantibodies, have been used to predict T1D in at-risk 
individuals (65, 66).  Following the loss of FPIR, preclinical subjects remain 
normoglycemic and have stable C-peptide levels months to years, until impairments in 
arginine-stimulated insulin secretion, the incretin response, and glucagon suppression are 
observed (67, 68).  Due to the difficulties in longitudinally assessing beta cell mass in 
T1D subjects (even with the aid of mathematical modeling), it is not known whether the 
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loss of insulin responses is the result of beta cell deficiency or beta cell dysfunction.  
Nevertheless, cumulative animal studies have suggested that the loss of acute phase 
glucose-stimulated insulin response is usually accompanied by marked changes in the 
beta cell phenotypes in T1D (69, 70).  Additionally, much in vitro work has shown that 
the proinflammatory cytokines present in the T1D milieu clearly cause beta cell 
dysfunction (through disrupting beta cell calcium homeostasis, activating the unfolded 
protein response, and/or elevating nitric oxide stress (71, 72)).  Based on above 
observations, it is proposed that beta cell dysfunction likely precedes beta cell destruction 
during the development of T1D.   
Clinical stage: 
Beta cell recovery 
Soon after diagnosis, patients receive exogenous insulin replacement therapy to 
manage blood glucose and to avoid the life-threatening ketoacidosis.  Interestingly, the 
administration of insulin often elicits a response that features near normal glucose 
metabolism and markedly decreased insulin requirements.  Though this disease remission 
phase was first documented in 1940 (73), the underlying mechanism was not addressed 
until the 1970s.  Based on the observation from a controlled clinical trial, Mirouze et al. 
proposed that the insulin treatment reduces the beta cells’ secretory burden, leading to 
enhanced insulin secretion and beta cell viability (74).  In addition, it was speculated that 
insulin therapy corrects glucotoxicity (observed around the time leading up to clinical 
diagnosis) and facilitates the functional recovery of beta cells.  This concept of beta cell 
rest and recovery was finally experimentally tested in 1980s, when Pipeleers, Eizirik, and 
colleagues reported that beta cells and rodent islets undergo functional recovery after 
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experimentally-induced damage (75-78).  They proposed that beta cells first become 
functionally impaired upon the autoimmune attack.  In this phase, different cellular repair 
mechanisms are activated.  However, depending on the context of challenge and the 
effectiveness of cellular repair mechanisms, beta cells might remain dysfunctional, die, or 
recover from assaults.  
To provide translational evidence of the discoveries from rodent studies to the 
human disease, a recent report from Sherry et al. documented that human beta cells 
indeed become degranulated in T1D (79).  This interesting observation raises several 
questions: 1) can human beta cells re-establish their insulin granules, 2) what have the de-
granulated beta cells become; are they considered de-differentiated or merely beta cells 
devoid of insulin, and 3) could beta cell recovery-enhancing agents be employed to 
promote the recovery of insulin granules and beta cell constitution?  Indeed, 
hyperglycemia in rodents can provoke beta cell de-differentiation to progenitor-like cells 
(70, 80, 81).  Additionally, beta cell de-granulation was observed in a primate model of 
T1D (82).  Likewise, culturing adult human beta cells in vitro induces cell de-
differentiation and subsequent proliferation of de-differentiated cells (83, 84).  Reverting 
the de-differentiated cells back to bona fide beta cells can be achieved in vitro (85), but 
the extent to which beta cell degranulation/de-differentiation, and subsequent re-
granulation/re-differentiation occurs during T1D is unclear.  Therefore, it is essential to 
perform lineage-tracing experiments in T1D animal models with a well-characterized 
disease remission phase to address the questions described above.  Also, re-examining 
whether or not the previously reported proliferating beta cells present in injury/diabetes 
models also have the de-differentiation markers (e.g., mesenchymal cell or early 
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progenitor cell markers), and rendering the cells transiently dysfunctional yet highly 
proliferative, is needed.  Moreover, it is likely that the proliferating beta cells observed in 
T1D are originated from alpha or other islet cell types (trans-differentiation) because it 
has been shown that beta cell injury may induce phenotypic changes of adjacent cells, 
such as transforming alpha cells into less-mature pro-alpha cells, thereby making them 
capable to transiently express beta cell genes (86).  Besides, in most T1D animal models, 
increases in alpha and delta cell numbers are often observed following the onset of 
autoimmune activation and/or beta cell damage (87, 88).  It will be informative to 
examine whether or not these newly generated cells could trans-differentiate into beta 
cells.  On the other end of spectrum, high-throughput analyses on pancreatic samples 
collected from patients in the honeymoon phase (or samples from chemically-induced 
diabetic primates receiving islet xenografts) may facilitate the identification of key genes 
and proteins involved in beta cell recovery.  Once the functional relevance of the 
recovery genes is validated in knockout mouse models, strategies can be designed to 
foster the functional integrity of the remaining beta cells and promote the recovery of 
damaged beta cells, therefore prolonging the honeymoon phase (e.g., create a T1D 
remission).   
From a clinical perspective, promoting beta cell recovery is suitable for 
therapeutic implementation because new-onset T1D patients still possess ~20% of their 
initial beta cell mass, and their insulin secretory responses to a mixed meal glucose 
tolerance test are about 50% of normal healthy control subjects (89).  In addition, 
stimulated C-peptide levels from new-onset T1D patients remain clinically significant 
(29).  As even slight preservation of insulin production can significantly improve 
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metabolic control (thereby reducing the risk of developing retinopathy, nephropathy, 
hypoglycemic episodes, and other diabetes complications) (90), it is extremely important 
to preserve the remaining beta cells.  In short, promoting beta cell recovery and survival 
is the most straightforward and attainable approach deserving more attention 
experimentally. 
Beta cell regeneration 
During the progression of T1D, the inflammatory insults have been suggested to 
trigger beta cell proliferation or transdifferentiation in rodents (79, 87, 91).  Yet, whether 
these phenomena occur in humans is still under debate.  Butler et al. first reported that the 
beta cell replication rate is not increased in recent-onset T1D patients (92); whereas 
Willcox et al. recently documented that the increased islet cell (alpha and beta cells) 
proliferation observed in newly diagnosed T1D patients was associated with the presence 
of insulitis lesions.  The later study also pointed out that beta cell proliferation, however, 
is not detectable in patients with longstanding T1D.  The explanation of such observation 
is that beta proliferation is limited by age-related factors (93, 94).  In other words, 
although beta cell replication rarely occurs in human adults, it is detectable in children 
and young adults (95, 96).  A supportive study from In’t Veld et al. also showed that 
younger patients with life support (which is correlated with higher levels of immune 
infiltration in pancreatic parenchyma) have higher beta cell proliferation rates (97).  On 
the contrary, chemically-induced diabetic primates failed to display any beta cell 
replication, most likely because the monkeys used in those studies were adults (82, 98).  
However, small clusters of beta cells adjacent to ducts, as well as beta cells bearing other 
endocrine markers were found in the diabetic monkeys (82, 98).  In short, whereas beta 
 	   27	  
cell proliferation possibly occurs in newly diagnosed T1D juveniles, beta cell 
transdifferentation may be detectable in youth and adults.  Future studies will need to 
address whether immune insults can promote beta cell proliferation and/or neogenesis in 
different age-groups.  More importantly, if immune modulation suppresses beta cell 
regeneration, a combinatorial approach needs to be developed to simultaneously 
encourage the growth of beta cells.  
Beta cell destruction 
As T1D progresses, the immune infiltration, ambient hyperglycemia, and ER 
stress eventually accelerate the loss of beta cells.  Among the destructive factors, the 
immune attack is the main contributor of beta cell death.  Recently, a landmark study 
from Lebastchi et al. reported that the administration of an immune modulator 
(teplizumab, an anti-CD3 monoclonal antibody) decreased the rate of beta cell death in 
new-onset T1D patients (99).  The authors suggested, for the first time, that an immune 
therapy reduces the decline in C-peptide and the need for exogenous insulin, possibly by 
decreasing beta cell death.  This study nicely highlighted the importance of limiting beta 
cell death for attaining better glycemic control in T1D.  In addition, the molecular 
signaling networks involved in the immune-mediated beta cell destruction have been 
extensively studied in animal and cultured cell systems (100).  It is believed that under 
autoimmune challenges, beta cells are destroyed by direct contact with activated 
macrophages and T cells, and/or exposure to pro-inflammatory cytokines, nitric oxide, 
and reactive oxygen species (100).  Such beta cell homicide may continue for years in 
humans (101).  Meier et al. initially claimed that beta cell apoptosis is detectable in long-
standing T1D patients (102).  Later, the same group observed an increased beta cell 
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apoptosis rate in new-onset T1D patients (92); and this notion was supported by Akirav et 
al. via a novel methylation-specific PCR assay (103).  Excitingly, this new methodology 
(e.g., detecting beta cell death events with assays using serum) enables researchers to 
measure beta cell death in a non-invasive way, thereby permitting us to study: 1) if beta 
cell death is halted by insulin therapy in the honeymoon phase, 2) do immune modulators 
other than teplizumab prevent beta cell death, and 3) could we use the apoptotic index, 
coupled with other biological markers, to predict the onset of T1D? 
Apart from immune-mediated destruction, the hyperglycemic environment in 
T1D may directly destroy beta cells, and/or indirectly elevate ER stress that causes beta 
cell dysfunction and death (60, 104, 105).  It has been suggested that ER stress genes 
such as ATF4 are increased in human islets collected at the onset of T1D (105).  
Interestingly, Engin et al. demonstrated that the UPR genes ATF4 and spliced XBP-1 are 
dysregulated in beta cells acquired from T1D donors.  Further, the administration of the 
chemical chaperone taurourosodeoxycholic acid protects pre-diabetic NOD mice from 
developing diabetes (106).  In other words, ER stress due to abnormal blood glucose 
fluctuations and immune insults may have been present before the initiation of beta cell 
death, which precedes the onset of T1D.  As Dr. Eisenbarth suggested, the susceptibility 
of T1D is analogous to rocks on a hill, poised but requiring a push to determine which 
rock rolls down the hill (107).  It is, therefore, critical to halt the disease progression at 
the early steps to prevent beta cell destruction and the subsequent development of T1D. 
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1.1.4 Treatments 
Substantial advancements had been made in last 30 years in finding strategies to 
prevent, predict, and/or reverse T1D (108).  Unfortunately, none of the tested therapies 
have persistent effects.  Moreover, these therapies are less convenient to employ 
(compared to the currently available insulin therapies) and often come with significant 
side effects (109).  With the support from well-organized clinical trial networks and 
registries, the field must better define disease heterogeneity and identify more practical 
and effective therapies to prevent or reverse T1D (61).  
Because algorithms to predict T1D are improving, several large-scale clinical trial 
centers are investigating how to prevent (primary prevention) or delay (secondary 
prevention) the onset of diabetes. 
Primary prevention trials target genetically high-risk individuals without islet 
autoimmunity.  The most common primary prevention trials involve dietary intervention.  
For example, the Trial to Reduce Incidence of Diabetes in a Genetically at Risk study 
(TRIGR) investigates if T1D can be prevented by restricting infants’ exposure to cow 
milk (110, 111), given: 1) diabetes-prone biobreading rats and NOD mice fed a complex 
weaning diet are prone to develop diabetes (because the complex diet triggers islet 
autoimmune reactions); whereas amino acids- or extensively hydrolyzed casein-fed 
rodents are protected from the development overt diabetes, and 2) previous observations 
demonstrated that the early weaning to cow’s milk-based formula is a diabetes risk factor 
(112).  Unfortunately, based on recent reports (5- and 7- years follow-ups), a formula-
based diet exhibited no protection against T1D (113, 114).  Currently, the TRIGR study 
group is collecting more test results to determine if a formula-based diet protects against 
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T1D at the 10 year follow-up.  Meanwhile, other small-scale trials such as the 
BABYDIET study (delaying gluten exposure) (115), and the Nutritional Intervention to 
Prevent T1D (NIP) study (docosahexaenoid acid/DHA supplementation in infant 
formula) (116), are still in the pilot study phase.  To date, none of the dietary 
interventions yield improvements in preventing T1D development (117).  
Secondary prevention trials are conducted in autoantibody positive individuals 
before their clinical diagnosis of T1D.  The most famous study is the European 
Nicotinamide Diabetes Intervention Trial (ENDIT).  The ENDIT study employed 
nicotinamide (which mediates cellular NAD+ and ATP production) as a cytoprotective 
agent to preserve beta cells in order to delay T1D development (118).  Another large-
scale study is the Diabetes Prevention Trial Type 1 (DPT-1). DPT-1 utilized oral insulin 
treatment (to metabolically and/or immunologically preserve beta cells) to delay the onset 
of T1D (119).  However, neither of these two studies documented an improvement in 
delaying T1D development.  Indeed, it is very difficult to identify universal therapies to 
prevent T1D because different individuals possibly respond to interventions differently. 
Other than trying to prevent and/or delay the development of T1D, much work 
has been dedicated to finding a cure for T1D.  Unfortunately, there is no permanent cure.  
Currently, immune-modulation and the pancreas/islet transplantation are the only 
strategies likely to be employed to reverse T1D.   
The goals of reversal trials are to preserve the production of C-peptide and induce 
immune tolerance, thereby halting beta cell destruction.  Past approaches concentrated on 
employing systemic immunosuppressants, which have notorious side effects.  Recent 
approaches include non-antigen specific trials (e.g., CTLA-4 antibody, TNF-α antagonist, 
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HSP60, anti-CD3 antibody, anti-CD20 antibody, and autologous non-myeloablative 
hematopoietic stem cell transplantation) (61), and antigen specific trials (e.g., Alutamic 
acid decarboxylase vaccination (120)).  Unfortunately, none of these approaches have 
long-lasting effects.  The anti-CTLA-4 therapy was able to slow down the reduction of 
beta cell function for up to 2 years (121, 122), and HSP60 yielded only 1-year C-peptide 
preservation (123). 
Compared to immune modulating trials, pancreatic transplantation is considered 
the only cure for T1D, with a 5-year post-surgery survival of  ~90%.  The graft survival 
rate is ~60% at 5 years post-transplantation, with a half-life of 7-14 years (124).  
Compared to the effective pancreas transplantation, islet transplantation still remains an 
experimental procedure.  Other than pancreas and islet transplantation, stem cell-based 
therapies have recently received considerable attention.  However, many hurdles remain, 
including: how to generate functional beta cells (125, 126), how to vascularize the graft, 
where to transplant the graft (127), and so on.  In short, better understanding of the 
pathogenesis of T1D is required for harnessing immune regulation and beta cell 
regeneration therapies to prevent/reverse T1D.    
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1.2 Type 2 diabetes 
Type 2 diabetes (T2D) accounts for 90-95% of diabetes.  Patients with T2D 
predominantly present with insulin resistance coupled with an insulin secretory defect or 
relative insulin deficiency (128). 
1.2.1 Epidemiology and diagnosis 
The global prevalence of T2D has been increasing rapidly in the last three 
decades, particularly in youth and children (129).  By 2030, about 396 million people are 
expected to have T2D (130).  This remarkably high prevalence of T2D has created an 
enormous public health burden.   
Most patients with T2D are obese or have increased body fat distribution in the 
abdominal region.  However, obesity itself is insufficient for causing diabetes as only 
30% of people with obesity develop T2D.  People ultimately developing T2D may 
remain undiagnosed for years, because their hyperglycemia develops slowly and largely 
unnoticeably.  The diagnostic criteria for diabetes are: 1) HbA1C ≥ 6.5%, 2) fasting 
plasma glucose ≥ 126 mg/dl, 3) plasma glucose level ≥ 200 mg/dl at 2-h post oral glucose 
tolerance test, or 4) random plasma glucose ≥ 200 mg/dl.   
People with intermediate plasma glucose levels, yet not clinically categorized as 
diabetetics, are considered to have pre-diabetes; the ADA classifies these subjects as at a 
“High Risk State of Developing Diabetes”, and WHO prefers the term “Intermediate 
Hyperglycemia” instead of pre-diabetes (128, 131).  The laboratory test results 
representing pre-diabetes are: 1) fasting plasma glucose of 100-125 mg/dl (impaired 
fasting glucose, IFG), 2) 2-h post-load glucose of 140-199 mg/dl (impaired glucose 
tolerance, IGT), or 3) A1C range from 5.7-6.4%. 
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1.2.2 Etiology of T2D 
T2D, like T1D, is a multi-factorial disease dependent on a mix of genetic and 
environmental factors.  T2D is driven by chronic fuel surfeit in genetically susceptible 
people (132).  The factors contributing to the development of T2D are discussed below. 
It has long been accepted that genetic factors contribute to the development of 
T2D.  The first supporting observations arose from an early population study, in which 
specific ethnic groups were identified to have a higher prevalence of T2D (133).  Later, 
heredity studies revealed that the T2D concordance rate in monozygotic twins was much 
higher than dizygotic twins (134-136), and the risk of developing T2D is greater if 
parents have T2D (137).  These findings and others suggested that genetic predisposition 
could be a triggering factor of T2D.  Recently, more than 60 common genetic variants 
associated with T2D were identified via GWAS, linkage analysis, and candidate gene 
approaches.  Interestingly, many of the T2D susceptibility genes are, in fact, pancreatic 
beta cell genes.  For example, TCF7L2 (encoding transcription factor 7-like 2, regulates 
pro-glucagon gene expression levels) (138, 139) and KCNJ11 (encoding the potassium 
channel KIR6.2, regulates beta cell insulin secretion) variants are highly prevalent and 
linked to high T2D risk (140).  Other identified genes such as KCNQ and PPARG are 
related to insulin sensitivity; MC4R and FTO genes are related to obesity; CAPN10 is 
related to glucose transport (141).  Unfortunately, due to the polygenic nature of T2D, it 
is difficult to analyze a single gene’s contribution to the increased risk for diabetes.   
In addition to one’s genetic composition, epigenetic regulation and early life 
events also control the development of T2D (142).  For example, inadequate fetal 
nutrition increases the risk of developing T2D in adult life (143-145), and such risk could 
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be aggravated by subsequent nutrient over-exposure (146).  In addition, individuals 
exposed to gestational diabetes in utero also have a greater T2D risk (147).       
Other than the genetic components, the environmental factors such as the Western 
lifestyle (e.g., high-energy diet and decreased physical activity) is associated with 
diabetes development based on: 1) migration studies suggesting populations moving from 
rural to urban areas have increased obesity and T2D incidence (148, 149), 2) 
epidemiological studies demonstrating rapid lifestyle and dietary structure changes 
caused sharp increases in the prevalence of T2D in Asian countries (150, 151), and 3) 
studies suggesting a sedentary lifestyle is strongly associated with being overweight and 
developing diabetes (152, 153).  In contrast, a hypocaloric diet and exercise can reduce 
T2D risk.  Both dietary and lifestyle interventions have been well documented to improve 
metabolic parameters among people with impaired glucose tolerance, therefore reducing 
their T2D risk (154-156). 
1.2.3 The natural history of T2D  
T2D is a progressive disease characterized by beta cell dysfunction and insulin 
resistance-associated hyperglycemia.  From the clinical perspective, the progression of 
T2D can be separated into 2 stages: pre-diabetes (pre-clinical) and frank diabetes. 
Pre-clinical stage: 
According to the ADA and a Chinese diabetes prevention trial, up to 70-90% 
individuals with pre-diabetes will eventually develop diabetes (131, 157).  Thus, it is 
essential to identify individuals with pre-diabetes in a timely manner because early 
interventions can help prevent or delay the development of frank T2D and its 
complications (158).  In the clinic, non-invasive risk factor assessments, together with 
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laboratory blood glucose measurements, are sufficient for identifying pre-diabetic 
individuals (159).   
The first clinical abnormality observed in susceptible individuals is IGT, IFG, or 
both.  Interestingly, people with IGT usually have different pathophysiological 
abnormalities compared to those with IFG (160).  For example, individuals with IGT 
seem to have reduced muscle insulin sensitivity (yet their hepatic insulin sensitivity 
remains near-normal), reduced FPIR, and reduced second phase insulin release (161).  
Conversely, individuals with IFG usually have reduced hepatic insulin sensitivity and 
loss of FPIR.  These pathological differences underlying IGT and IFG may reflect the 
chronological sequence of T2D pathogenesis.  For instance, Prentki and Nolan have 
proposed a “fuel surfeit” etiology model of T2D, in which the pathogenesis of T2D starts 
with skeletal muscle insulin resistance (observed as IGT) (132, 162).  The rationale 
behind this hypothesis is that, muscles of susceptible people often fail to contain 
excessive nutrients in situ (163-165), prior to diverting extra nutrients to adipose tissue 
and liver (166).  Over time, the accumulation of lipid species in the plasma and tissues 
render muscle and liver insulin resistant (observed as IFG).  However, insulin resistance 
is just a triggering factor of T2D.  What drives the complete manifestation of T2D is the 
failure of pancreatic beta cells to secrete more insulin to fully compensate for systemic 
insulin resistance (167-170).   
Defective insulin secretion 
To maintain glucose homeostasis, insulin secretion is controlled by intricate 
cellular mechanisms.  Briefly, glucose influx into the beta cell raises the cytoplasmic 
calcium concentration and triggers insulin-containing secretory granule exocytosis (171).  
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Normally, insulin secretion oscillates to exert maximal hypoglycemic effects (172); and 
the pattern of oscillations is regulated by nutrients, hormones, and neuronal signals (173-
176).  However, in first-degree relatives of T2D, the post-meal insulin secretion 
oscillations are deranged (177).  Additionally, Polonsky et al. have reported inadequate 
glucose entrainment in IGT patients, signifying that the pre-diabetic individuals have lost 
the feedback loop between glucose and insulin secretion (178, 179).  Moreover, recent 
reports suggested that the oscillatory insulin release in human islets, as a coordinated 
event of glucose-induced calcium-mediated intra-islet electrical signal transmission, is 
perturbed by diabetogenic insults, again emphasizing that the early defects in insulin 
secretion could drive the development of T2D (180-184).   
Apart from the above-mentioned coordinated glucose-stimulated insulin secretion 
examinations, insulin secretion can be robustly assessed in the clinical settings via: 1) 
intravenous tests, including intravenous glucose tolerance testing (IVGTT) and 
hyperglycemic clamp techniques, or 2) an oral glucose tolerance test (OGTT).  Overall, 
the cumulative clinical reports indicate that: 1) the loss of FPIR is apparent in patients 
with IGT and/or IFG (169, 185-191), and 2) total insulin response during an OGTT is 
significantly decreased in pre-diabetic subjects.  Given that beta cell (dys)function cannot 
be evaluated based on insulin secretion without considering underlying insulin resistance, 
the disposition index (DI, the ratio of insulin increments to glucose increments divided by 
insulin resistance) is also employed to characterize beta cell function.  Not surprisingly, 
the hyperbolic relationship between insulin secretion and insulin sensitivity is altered in 
pre-diabetic subjects (192, 193).  
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Interestingly, beta cells might be able to secrete more insulin to compensate for 
insulin resistance in the pre-diabetic stage (194, 195).  In particular, Tabak et al. have 
drawn trajectory curves of fasting glucose, 2 h post-load glucose, insulin sensitivity, and 
beta cell function of the British civil servants during a 13-years time span in the 
Whitehall study (Figure 1-2) (131, 195).  In this landmark report, the authors 
demonstrated an increased blood glucose level and decreased insulin sensitivity as early 
as 13 years before T2D diagnosis.  However, these subjects’ blood glucose levels were 
maintained within a normal range, suggesting that enhanced insulin secretion might have 
already existed during the early stages of disease.  In fact, Ferrannini et al. have 
performed a cross-sectional study, and observed that insulin secretion is increased from 
lean NGT to obese NGT, plateaued in IGT, and decreased in T2D humans (192).  
However, in the same study, they showed that glucose sensitivity of beta cells is 
drastically decreased in IGT and T2D individuals.  This report strongly supports the 
notion that beta cells are able to provide more insulin to meet metabolic demands, but 
they eventually become dysfunctional, thereby leading to the development and diagnosis 
of T2D.  Of note, Tabak et al. documented a sudden increase in 2 h post-load glucose 
level and steep decline of insulin sensitivity prior to the drastic enhancement of beta cell 
function in the Whitehall study.  The discrepancies in the sequence of events occurring 
during the pre-diabetic stage in the two reports mentioned above merely reflect the 
different methodologies used: Tabak and colleagues used a homeostasis model 
assessment (HOMA2-%B) to assess beta cell function, which might have limited 
resolution in assessing insulin secretion dynamics.  Collectively, clinical observations in 
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past decades have clearly demonstrated that beta cell compensation followed by 
decompensation is inherent in T2D development. 
 
Figure 1-2   
 
Fasting and 2 h post-load glucose, insulin sensitivity, and beta cell function 
trajectories before the diagnosis of diabetes (Adapted from Tabak et al. (195)). 
 
Factors contributing to beta cell dysfunction  
On the cellular level, the pathogenic factors and mechanisms responsible for 
defective insulin secretion are under intensive investigation.  Currently, it is believed that 
the “susceptibility factors” first cause beta cell damage; and the “potentiation factors” 
such as glucotoxicity, lipotoxicity, islet amyloid polypeptide deposits, and inflammatory 
insults accelerate the disease progression (132). 
Glucotoxicity 
Although many believe that chronic hyperglycemia sabotages beta cell function, 
the supporting in vivo experimental evidence in humans is scarce.  In fact, in one study a 
24 h glucose infusion actually promoted insulin secretion in humans (196).  As prolonged 
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glucose infusion is not well tolerated in humans, it is difficult to recapitulate the authentic 
glucotoxicity in an experimental setting (197).  Fortunately, a chronic glucose infusion 
protocol is well established in rodent models.  In most animal studies, continuous glucose 
infusion has been suggested to enhance beta cell insulin secretion and promote beta cell 
mass expansion (198-200), although in some cases glucose infusion led to beta cell 
dysfunction (201).   
In contrast, ex vivo experiments yielded more unifying results – e.g., prolonged 
high glucose exposure damages isolated human islet function and integrity (202-205).  
Similarly, grafting human islets in hyperglycemic nude mice results in beta cell 
degranulation and rough ER expansion, and the grafted islets have reduced insulin 
content and impaired GSIS (203, 206).  The potential molecular mechanisms behind 
glucotoxicity-associated beta cell dysfunction are ER stress and oxidative stress (207) 
because: 1) ER signaling cascades are deranged and oxidative stress markers are elevated 
in islets from T2D patients (208-210); 2) isolated human islets treated with the potassium 
channel blocker diazoxide, which blocks insulin secretion, are partially protected from 
high glucose pretreatment-impaired GSIS, indicating beta cells may suffer from 
overstimulation-induced stress, and beta cell rest might be beneficial for restoring insulin 
content and release; and 3) rodent studies suggested that the failure to activate UPR in 
response to obesity promotes diabetes progression; conversely, overabundance of ER 
chaperones in beta cells prevented mice from developing high-fat diet-induced glucose 
intolerance (211, 212).   
The aforementioned experimental evidence indicates that chronic high glucose 
stimulation leads to detrimental effects in islets.  However, it’s important to note that 
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pronounced hyperglycemia does not develop until the later stages of pre-diabetes.  In 
other words, other factors contribute to beta cell dysfunction before the manifestation of 
glucotoxicity. 
Lipotoxicity 
Chronic exposure of pancreatic islets to excess free fatty acids (FFA) in the pre-
diabetic milieu is proposed to compromise beta cell function, based on the clinical 
observations reporting that: 1) plasma lipidome profiles in pre-diabetic subjects are 
strikingly similar to T2D patients (213), 2) saturated fatty acid composition in plasma is 
positively correlated with the incidence of T2D (214-216), and 3) pancreatic fat 
accumulation is increased in IFG and/or IGT individuals (217, 218).  This hypothesis has 
been tested under both in vivo and ex vivo settings.  For instance, elevated plasma FFA 
(via intralipid infusion) impairs beta cell function in obese non-diabetic humans as well 
as individuals with a family history of T2D (based on DI or absolute GSIS) (219-222).  
On the contrary, lowering plasma FFA has been proven effective in improving insulin 
secretion in the genetically predisposed individuals (223, 224).  In addition, culturing 
human islets with FFA results in detrimental effects in beta cells, including: 1) 
accumulated intracellular lipid droplets and triglyceride (204, 225), 2) increased 
inflammation and oxidative stress (226, 227), 3) increased ER stress (228), 4) 
dysregulated circadian gene expression profiles (229), 5) modified lipid metabolism gene 
expression profiles (230), 6) decreased insulin content, 7) diminished FPIR (determined 
by perifusion assays) and GSIS (measured using static culture protocols) (203, 225, 231), 
and 8) increased cell death (232, 233).	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Amyloid polypeptide deposits	  
Islet amyloid polypeptide (IAPP) deposit is already present in pre-diabetic 
primates (234, 235), and human adiposity (determined by BMI) is positively correlated 
with fasting plasma IAPP-like immunoreactivity (236).  However, how IAPP fibrils 
accumulate in human islets is still unclear.  Some suggest that IAPP is co-secreted with 
insulin, and the accumulation of IAPP may repress GSIS and promote beta cell death via 
a local inflammation-mediated machinery (237-239).  
Inflammatory insults 
Recent findings suggest that inflammatory markers are predictors of T2D 
development (240-242), and an inflammatory response may promote beta cell failure in 
T2D (243).  For example, treatment with high glucose or free fatty acids in isolated 
human islets induces the release of IL-1β  and other proinflammatory factors (244-246).  
Conversely, blocking IL-1β’s effects with the IL-1 receptor antagonist anakinra improves 
the DI of obese, insulin resistant, non-diabetic individuals (due to an improvement of beta 
cell function (247)).  Yet, a conflicting report from the Insulin Resistance Atherosclerosis 
Study reported that inflammation is related to insulin resistance but not decreased insulin 
secretion in the pre-diabetic state (248).   
Alternatively, histological examinations suggest that insulitis may exist in the pre-
diabetic pancreas, as islet fibrosis (a hallmark of chronic inflammation) is detected in 
diabetic patients (249).   Nevertheless, it would be extremely valuable if more pancreatic 
tissue samples from pre-diabetic subjects become available because no autopsy or 
gene/protein analysis studies to date have demonstrated the existence of infiltrating pro-
inflammatory cells in the IGT or IFG individuals.  
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Beta cell mass in the pre-diabetic stage 
Not only beta cell function, but also beta cell mass is dynamically modulated in 
pre-diabetic individuals.  Based on cross-sectional autopsy studies, many studies indicate 
that beta cell mass initially increases slightly with obesity or insulin resistance, and then 
gradually decreases in the context of the diabetic milieu (250-257).  Yet, despite years of 
intensive investigation, the main mechanisms promoting human beta cell mass expansion 
(e.g., proliferation, transdifferentiation, or neogenesis) and loss (e.g., cell death or de-
differentiation) have not been definitively determined, and the factors regulating human 
beta cell mass dynamics remain poorly defined (258, 259).   
Beta cell mass expansion 
The dominant driving force of beta cell mass expansion in rodents is beta cell 
proliferation.  In contrast, primates have a relatively limited beta cell regeneration 
capacity (260, 261); yet, beta cell neogenesis, rather than proliferation, has been reported 
to facilitate beta cell mass expansion in insulin resistant humans (256, 257, 262).  The 
refractoriness of the mechanisms of beta cell mass expansion between rodents and 
primates could be attributed to age-related factors.  For instance, young rodents typically 
do not develop spontaneous diabetes and are largely resistant to diet-induced diabetes, 
possibly because the young animals used in most T2D studies have a greater beta cell 
proliferation capacity; hence they acquire sufficient beta cell mass to compensate for 
insulin resistance.  On the other hand, experimentally identified factors that prevent 
animals from developing experimental diabetes actually may have more subtle effects 
(e.g., improve beta cell function and survival), yet these effects are overshadowed by the 
massive enhancement of beta cell proliferation.   
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Another major hurdle in the field is to determine whether or not beta cell mass 
expansion occurs in pre-diabetic humans.  Although obese individuals have higher beta 
cell mass compared to lean control individuals, it remains to be determined if such a 
phenotype is the result of compensatory beta cell mass expansion or from predetermined 
genetic traits (263).  If human beta cell mass expansion occurs in vivo, the next grand 
challenge will be to identify the factors promoting such events.   In fact, whereas the 
paradigm of nutrient- and hormone-induced beta cell proliferation has been 
comprehensively examined in rodents, few factors can efficiently induce human beta cell 
proliferation in vitro.  In addition, it is essential to examine if the newly replicated and/or 
regenerated beta cells are fully functional and whether they remain viable in the pre-
diabetic environment (264).   
Beta cell death 
At the other end of the spectrum, the factors leading to beta cell loss before the 
onset of diabetes are yet to be elucidated.  Pioneered by the work from Butler et al., most 
consider beta cell death the main contributor of beta cell loss (250, 260, 265).  This 
hypothesis has become so well accepted because numerous in vitro studies have 
successfully demonstrated that glucotoxicity, lipotoxicity, inflammatory mediators, or 
combinations of these insults promotes cultured beta cell and human islet destruction via 
apoptotic cell death pathways (205, 266).  However, induction of hyperglycemia and 
diabetes in rodents and non-human primates by high fat feeding alone seems unable to 
evoke substantial beta cell death (267-269).  The reason could be current technology is 
insufficient to capture the in vivo cell death events.  Indeed, to date no 
clinical/histological reports document increased beta cell death in pre-diabetic individuals.   
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Nevertheless, a better understanding of stress-induced beta cell death mechanisms 
would promote the discovery of new therapeutic strategies in the field of transplantation 
and regenerative medicine.  Until now, human beta cell transplants (either from cadaveric 
origin or stem cell-derived beta cells) quickly become dysfunctional and die shortly after 
transplantation.  It is urgent to seek methods to foster the survival and function of the 
grafts.  Indeed, several approaches (e.g., enhancing islet revascularization, eliminating 
blood-mediated inflammatory reactions, introducing antioxidants, resolving ER stress, 
and utilizing mesenchymal stem cell-derived factors (270, 271)) are currently under 
intensive investigation. 
Beta cell de-differentiation 
Recent thought-provoking reports from the Accili laboratory suggested that 
glucotoxicity perhaps contributes to beta cell de-differentiation, rather than apoptosis 
(272).  Although the concept of the loss of beta cell identity (defined by decreased 
expression of genes characteristic of beta cells and a loss of glucose responsiveness) in 
the diabetic milieu is far from new (273), Accili’s group revealed that beta cells lacking 
the transcription factor Foxo1 could turn into progenitor-like cells and subsequently 
adopt an alpha cell fate following physiologic stress.  Interestingly, they did not observe 
beta cell death or beta cell self-renewal under their experimental settings (e.g., aging and 
pregnancy) (272).  Supporting data from Nichols’s groups suggested that beta cell KATP 
channel gain-of-function mice (reiterating features of human neonatal diabetes) develop 
diabetes due to beta cell inexcitability and subsequent de-differentiation.  More strikingly, 
reversing hyperglycemia in these mice leads to re-differentiation of mature beta cells 
(274, 275).  Apart from the above mechanistic studies, only a few immunohistological 
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studies have reported de-differentiation events in primates (256, 267, 273).  Indeed, why 
beta cell de-differentiation, rather than beta cell death, should be a preferred mechanism 
in response to diabetic milieu is not clear.  Possible explanations could be: 1) it may be 
more energy efficient to keep cells alive, so that the beta cells can strive to survive 
through stressful conditions and return to their original functional states, rather than 
undertaking the energy-expensive cell death and mitosis processes. 2) In the 
hyperglycemic milieu, beta cells release and sense the soaring level of insulin.  As a first-
line self-protective mechanism against the development of hyperinsulinemia-induced 
hypoglycemia, beta cells might transiently be re-programmed to glucagon secreting cells.  
In brief, although the de-differentiation hypothesis is groundbreaking, much work is still 
needed to establish the endocrine pancreas plasticity/hierarchy under pathological and/or 
regenerative settings to ultimately facilitate the discovery of therapeutic strategies to 
expand/maintain functional beta cell mass.   
Overall, as current non-invasive technology to measure beta cell mass is still not 
available for humans, it remains difficult to determine the natural history of beta cell 
expansion and loss, not to mention to dissociate the contribution of beta cell dysfunction 
and beta cell loss, in the progression of T2D.  Apart from human autopsy and biopsy 
studies, future research aimed at identifying early biomarkers and/or that using invasive 
large animal models will help elucidate the chronological order of beta cell failure events 
that lead to the development of T2D.   
 
Clinical stage: 
The majority of the pathological events initiated in the pre-diabetes stage only 
deteriorate with time following diagnosis.  For example, 1) beta cell mass in the 
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diagnosed T2D patients is 40-50% less than healthy individuals, and beta cell mass in 
T2D patients is inversely correlated with the duration of the disease (254), 2) beta cell 
functional parameters (e.g., first phase insulin secretion (276), ultradian and high 
frequency insulin secretion oscillations (277-279), and glucose sensing (280, 281)) are 
markedly reduced in T2D patients, and 3) beta cell loss is associated with IAPP 
deposition in T2D patients (282); whereas islet amyloidosis severity is correlated with 
increased fasting plasma glucose and HbA1c as well as decreased beta cell mass in 
primates (283).  The aforementioned beta cell dysfunction and destruction events in 
diagnosed T2D patients indeed implicate a loss of cellular protective mechanisms and 
deranged beta cell homeostasis.  For instance, a recent study from Engin et al. suggests 
that the UPR markers are disturbed (instead of systematically up- or down-regulated) in 
cadaveric islets from T2D patients (210).  Further, hypoxia-inducible factors are induced 
by acute hyperglycemia; however, chronic hyperglycemia curtails most of the hypoxia-
responsive elements in beta cells (284).  These observations strongly suggest that T2D as 
a disease of dysregulated metabolic homeostasis; and at the late-stage of diabetes, most 
adaptive responses likely have failed.  
1.2.4 Treatments 
Current anti-diabetic interventions aim to improve insulin sensitivity and restore 
beta cell function in different stages of the disease (285).  In the pre-diabetic stage, 
lifestyle changes can increase baseline beta cell function and insulin sensitivity toward 
NGT (157, 286-288); and reversion to NGT is associated with significantly reduced T2D 
risk (289).  In newly diagnosed patients, insulin therapy, an IL-1β antagonist, and GLP-1 
receptor agonists have been shown to temporarily restore beta cell function.  Indeed, 
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there are many medications available for T2D patients to achieve and maintain closer-to-
normal blood glucose levels (e.g., metformin, sulfonylureas, incretins, and insulin).  With 
increasing therapeutic options, practitioners often utilize a patient-centered approach, 
together with consensus treatment initiation/adjustment algorithms to treat patients (290-
293).   
Ultimately, the goals of anti-diabetic therapy are to preserve the existing beta cells, 
and to restore/expand functional beta cell mass.  Below, I discuss the potential 
applications of growth factor-related therapies. 
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1.3 Mitogenic signals control functional beta cell mass  
To produce adequate amounts of insulin to guarantee tight glycemic control, 
functional beta cell mass increases and decreases in response to different 
(patho)physiological conditions.  For instance, pregnancy induces beta cell mass 
expansion; yet after parturition, the beta cell mass declines (294).  Conversely, 
pathological stimuli such as insulin resistance, hyperglycemia, and tissue injury also 
promote beta cell mass expansion (295, 296).  On the molecular level, glucose, insulin, 
insulin-like growth factor, incretins, lactogens, hepatocyte growth factor, parathyroid 
hormone-related protein, epidermal growth factor (EGF), betatrophin, and liver-derived 
mitogenic signal have been suggested to promote beta cell mass expansion (199, 255, 
297-300).   
Unfortunately, despite work over the past three decades that has significantly 
increased our understanding of how mitogen signaling pathways promote beta cell 
proliferation in rodent models, the feasibility and translation of mitogen-derived therapies 
to humans remains poor.  Some possibilities for the inability to translate these therapies 
are: 1) species differences, as rodents display a relatively large beta cell proliferation 
response in contrast to that found in humans, 2) age-related factors, as most diabetes 
studies use young rodents when the beta cells have a high replication capacity, and 3) the 
lack of understanding of how mitogenic signaling pathways are regulated during the 
diabetic conditions.  Though several mitogenic signaling cascades have been shown to 
prevent T1D/T2D and reverse early-stage T1D, none of them have cured fully developed 
diabetes.  In other words, mitogenic signaling pathways might be differentially regulated 
in the diabetic milieu.  For instance, pathogenic stress may impose barriers that inhibit the 
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beneficial effects of the mitogen therapies.  In order to close the knowledge gap and 
potentially use mitogens to treat diabetes, mitogen-mediated beta cell regeneration and 
recovery mechanisms must be examined in diabetic states.  
1.3.1 ErbB receptor tyrosine kinase signaling pathways in the pancreas 
The ErbB receptor family has four members: EGFR/Human epidermal growth 
factor receptor-1 (HER1)/ErbB1, Neu/HER2/ErbB2, HER3/ErbB, and HER4/ErbB4 
(301).  These ErbBs contain an extracellular ligand-binding domain, a trans-membrane 
domain, and an intracellular tyrosine kinase domain (with the exceptions that ErbB2 does 
not have a functional ligand-binding domain and ErbB3 does not contain an intracellular 
kinase domain) (302).  Upon ligand binding (EGF, heparin-binding EGF-like growth 
factor/HB-EGF, transforming growth factor-α/TGF-α, amphiregulin/AR, 
betacellulin/BTC, epiregulin, neuregulin/NRG, or epigen), the receptors either homo- or 
hetero-dimerize to facilitate intracellular kinase activation, and then recruit adaptor 
proteins and activate the Extracellular signal-regulated kinase (ERK) and 
phosphoinositide 3-kinase (PI3K) pathways to control cell growth, differentiation, and 
survival (301).   
EGFR and its ligands in the pancreas 
In the neonatal developmental stages, EGFR is expressed throughout the 
gastrointestinal tract.  After birth, EGFR becomes restricted in the pancreatic islets and 
pancreatic ducts (303).  The significance of EGFR in controlling pancreatic development 
has been demonstrated by EGFR knockout mice: EGFR-/- mice exhibit defective 
pancreatic branching morphogenesis, streak-like islets, and reduced beta cell mass (304).  
Not surprisingly, EGFR-/- mice die soon after birth due to multi-organ failure.  In order to 
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study the roles of EGFR in the pancreas beyond the developmental phases, pancreatic and 
duodenal homeobox-1 (Pdx-1)-driven EGFR kinase dominant-negative (EGFR-DN) mice 
were generated (305).  Interestingly, the EGFR-DN mice have reduced beta cell 
proliferation rates, decreased beta cell mass, and developed spontaneous diabetes.   
On the other hand, independently deleting EGF, AR, BTC, or TGF-α peptides has 
no observable effect on the development or maturation of pancreatic islets, indicating that 
high levels of functional redundancy exists among EGFR ligands (306).  However, in the 
in vitro setting, BTC induces differentiation of embryonic explants towards a beta cell 
lineage (307, 308); whereas supplementing with EGF or TGF-α promotes ductal cell 
proliferation and differentiation in the isolated fetal pancreas (309-311).  
ErbB2, ErbB3, ErbB4 and their ligands in the pancreas 
Compared to EGFR, the other ErbB receptors (ErbB2, ErbB3, and ErbB4) are 
predominantly expressed in the pancreatic ducts during development (312, 313).  The 
loss of ErbB2 or ErbB4 causes early (before pancreas formation) embryonic lethality, 
whereas ErbB3 knockout mice have an irregular pancreatic structure.    
The ligands of ErbB3 and ErbB4 are HB-EGF, BTC, and NRG.  Among them, 
NRG not only stimulates differentiation of pancreatic delta cells, but also supports the 
development of alpha cells in embryonic pancreas explants (307).  Whereas the 
underlying mechanisms are not clear, this observation indicates that the ErbB receptors 
and their ligands are fundamental in controlling pancreas development and progenitor 
cell fate determination.       
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1.3.2 EGF and EGFR control nutrient-induced beta cell mass expansion  
Functional beta cell mass is precisely controlled by nutrient availability and 
systemic insulin sensitivity.  Whereas 7-d high-fat feeding enhances insulin secretion and 
beta cell proliferation in 2-month-old mice (269), 72 h glucose and lipid infusion 
promotes beta cell mass expansion through EGFR and mammalian target of rapamycin 
(mTOR) signaling pathways in 6-month-old rats (314).   However, compensatory beta 
cell mass expansion is not observed in 1-year-old high fat-fed mice (315).  Whether or 
not chronic nutrient oversupply abrogates EGFR signaling cascades (e.g., by reducing 
EGF/EGFR levels or dampening EGFR activation) and/or facilitates the beta cell 
decompensation remains unknown.  
EGF levels in the diabetic pancreas 
Indeed, systemic EGF deficiency has been associated with diabetes mellitus, as 
diabetic rodents and humans have: 1) decreased EGF production/secretion from salivary 
glands (316-320), and 2) increased EGF excretion by the kidney (321, 322).  At the level 
of the pancreas, decreased EGF uptake by pancreatic cells is observed in diabetic NOD 
mice (323).  Yet, three important questions remain: 1) are pancreatic EGF and EGFR 
levels/uptake reduced in human T1D and T2D, 2) does the circulating or pancreatic EGF 
level correlate with the activation status of EGFR, and 3) does EGF-induced EGFR 
activation promote beta cell survival and/or regeneration in diabetic states? 
EGF as a potential treatment for diabetes 
Because the plasma EGF concentration is reduced in diabetic states, it is intuitive 
to consider using EGF as a treatment to promote beta cell recovery and regeneration, 
given its mitogenic potential.   In fact, activation of EGFR signaling cascades has been 
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suggested to facilitate tissue remodeling and repair (324).  For instance, EGF therapy has 
demonstrated positive effects in treating necrotising enterocolitis and high-grade diabetic 
foot ulcers (325) and has been used to facilitate skin wound healing and gastrointestinal 
ulcer healing in phase I-IV and double-blind randomized-controlled clinical trials (326-
329).  Most importantly, EGF-related therapies have been tested for potentially 
improving glycemic control.  Beginning in 2007, Transition Therapeutic Inc. (later 
partnered with Eli Lilly & Co.) reported a series of trials combining a gastrin analog 
(gastrin has been shown to induce EGF production (330)) and a GLP-1 analog (GLP-1 
has been suggested to trans-activate EGFR in the beta cells (331)) to treat both T1D and 
T2D patients.  These clinical assessments were terminated in 2010 because the 
company’s latest randomized, double-blind, placebo-controlled study failed to meet the 
efficacy endpoints.  If the reasons of such ineffectiveness could be identified, EGF-
related therapies may then be used to target diabetes because: 1) EGF is very well 
tolerated in humans, 2) the only reported side effect of long-term EGF treatment (even at 
supra-physiological concentrations) is epithelial hyperplasia and such symptoms are 
reversed by withdrawal of EGF, and 3) administration of EGF does not induce 
carcinogenesis in mice and humans (332-334).  Future mechanistic studies focusing on 
EGFR signaling cascades will encourage the clinical translation of EGF. 
EGFR signaling cascades regulate beta cell mass expansion in animal models of 
diabetes 
Many groups have established that EGFR is central to compensatory beta cell 
mass expansion.  Otonkoski’s laboratory has demonstrated: 1) pancreatic specific EGFR 
kinase-negative (EGFR-DN) mice failed to acquire high-fat diet- and pregnancy-induced 
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beta cell mass expansion, due to insufficient beta cell proliferation, and 2) constitutively 
active EGFR transgenic mice are protected against streptozotocin-induced diabetes, as 
the activation of EGFR protects beta cells from cytokine-mediated cell death (335, 336).  
On the other hand, Rabinovitch and others have shown that EGF and gastrin treatments: 
1) increase beta cell mass and reverse hyperglycemia in NOD or STZ/alloxan-induced 
diabetic mice (337-340), 2) increase implanted human beta cell mass and improve beta 
cell function in immunodeficient nonobese diabetic-severe combined immune deficiency 
(NOD-SCID) mice (341), and 3) delay autoimmune diabetes recurrence in NOD mice 
transplanted with syngenic islets (342).  Recently, Baeyens et al. further demonstrated 
that treatment with the combination of EGF and ciliary neurotrophic factor partially 
restores beta cell mass in STZ-induced chronic hyperglycemic mice via reprogramming 
acinar cells into beta cells (87).  
However, overt diabetes could not be cured by EGF therapy.  Wang et al. recently 
suggested that in addition to EGF, a concomitant immune-modulation should be 
employed to reverse hyperglycemia in late-stage NOD mice (343).  In this innovative 
study, the authors stated that the diabetogenic stress (autoimmune assault) has to be 
abrogated to allow EGF to exert its maximal cytoprotective and regenerative effects on 
beta cells.  Indeed, the activation of EGFR could be hindered by various pathological 
stimuli (344, 345).  For example, EGFR is subject to advanced glycation end product 
(AGE) modification (the addition of glucose to a protein without involvement of an 
enzyme) and inactivation during hyperglycemia, and such modifications are associated 
with delayed epidermal wound healing in diabetic mice (346-348).  Contradicting this, 
acute stress stimuli induce ligand-independent EGFR activation, resulting in non-
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canonical intracellular receptor trafficking and aberrant molecular actions in various 
cancer cell types (349-351).  It would be interesting to determine: 1) if acute and chronic 
stress initiate different EGFR activation networks, 2) whether primary and transformed 
cells have different reactions to stress stimuli in the context of EGFR 
activation/inactivation, 3) how EGFR activation status dictates tissue recovery in vivo, 4) 
what are the molecular mechanisms controlling EGFR dynamics under diabetic stress 
conditions in the pancreatic beta cells, and 5) are stress-responsive EGFR negative 
regulators involved in these processes.   
1.3.3 Negative regulators of EGFR signaling pathways 
Fortunately, many studies have led to the identification of stress-induced 
regulators of EGFR and its downstream signaling.  As a master regulator of cell fate, the 
EGFR signaling cascade is one of the most comprehensively studied molecular pathway 
(302). EGFR activation begins with the ligand-induced conformational changes of the 
EGFR juxtamembrane domains, leading to activation of one of the intracellular EGFR 
kinase domains.  The carboxy-terminal lobe (C-lobe) of the activated kinase molecule 
then binds to and stimulates the amino-terminal lobe (N-lobe) of the second kinase 
molecule.  Once dimerized and fully activated, EGFR undergoes endocytosis and 
propagates downstream signals.  Gradually, the EGFR signalosome is disintegrated and 
deactivated before trafficking to the lysosomes for degradation.  To ensure the proper 
cellular signal transmission, EGFR activity is controlled by tiers of negative regulators 
(301). 
The first tier of negative regulators consists of pre-existing components that 
trigger rapid inhibitory responses (e.g., controlling receptor tyrosine kinase (RTK) 
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phosphorylation and EGFR endocytosis).  RTK phosphatase SH2-containing 5'-inositol 
phosphatase (SHIP2) and protein tyrosine phosphatase 1B (PTP1B) are two such 
negative regulators implicated in promoting EGFR dephosphorylation and degradation 
(352, 353).  RTK endocytotic machinery could be central in maintaining cell integrity, 
and diabetic stress conditions have been shown to disrupt RTK endocytosis.  For 
example: 1) deregulated RTK endocytosis is observed in cells derived from diabetic mice 
(354), and 2) the perturbation of EGFR plasma-to-early endosome trafficking is 
associated with elevated intracellular cholesterol (355).  Interestingly, the RTK 
phosphatase SHIP2 gene and protein expression levels are elevated in the beta cells of 
diabetic animals.  In addition, SHIP2 and PTP1B have been reported to control beta cell 
proliferation and insulin secretion (356-358).    
The second (delayed) tier negative regulators undertake the spatial and temporal 
compartmentalization of EGFR, thereby shaping the cellular phenotypic responses.  This 
group of negative regulators includes: 1) the scaffold proteins that become inhibitory only 
after being modified by activated EGFR, 2) transcriptionally induced molecules that 
directly bind to EGFR and repress its RTK activity, and 3) inducible inhibitors of the 
mTOR, PI3K/Akt, and RAF/MEK/ERK signaling pathways.  Among the second tier 
regulators, increasing attention has been paid to characterize the transcriptionally induced 
EGFR inhibitors.  To date, four inducible feedback inhibitors have been identified in 
mammals: leucine-rich and immunoglobulin-like domains protein 1 (LRIG1), suppressor 
of cytokine signaling 4 and 5 (SOCS4 and SOCS5), and mitogen-inducible gene 6 (Mig6).  
Among them, Mig6 is the only EGFR feedback inhibitor that has been implicated in 
metabolic diseases. 
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1.3.4 Mitogen-inducible gene 6 
The human Mig6 (also called receptor-associated late transducer/RALT, ERBB 
receptor feedback inhibitor 1/Errfi1, and gene-33) gene is located on chromosome 1p36.  
It has 5 exons, encodes a 3144 bp mRNA, which is translated into a 50 kDa cytoplasmic 
protein containing an EGFR binding domain, a Cdc42/Rac-interaction and binding 
(CRIB) domain, a 14-3-3 protein binding motif, and a Grb2 binding motif.   
Mig6 inhibits EGFR activity via the aforementioned first- and second-tier 
mechanisms.  At the first tier (immediately after ligand binding and EGFR activation), 
Mig6 acts as an adaptor protein that recruits AP-2 and intersectins that facilitates clathrin-
mediated EGFR endocytosis, and engages sytaxin 8 that directs EGFR toward the late 
endosome-to-lysosome degradation pathways (359, 360).  The second tier of Mig6-
mediated inhibition involves an allosteric inhibition of EGFR kinase activity (361).  
Based on crystallography and biochemical binding studies, Mig6 binds to the C-lobe of 
the EGFR kinase domain and interrupts the formation of asymmetric dimers (361, 362).  
It is likely that, in the EGFR activation programs, pre-existing Mig6 first disrupts the 
EGFR signalosome by enhancing the lysosomal routing.  Later, de novo mitogen-induced 
Mig6 further prevents the activation of plasma membrane EGFR.  Taken together, Mig6 
provides robust and lasting inhibitory functions to repress EGFR activity.    
Transcriptional and translational regulation of Mig6 
Mig6 transcription is rapidly induced by mitogens (e.g., EGF, insulin, hepatocyte 
growth factor, platelet-derived growth factor, and transforming growth factor alpha 
(363)) and stress stimuli (e.g., cytokines, hypoxia, osmotic stress, and mechanical strain 
(364, 365)).  Because Mig6 is an effective EGFR inhibitor, cellular Mig6 mRNA and 
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protein levels are tightly controlled.  For instance, epigenetic modifications alter Mig6 
expression levels in human lung cancer and melanoma cell lines (366), and the 
transcription of Mig6 is controlled by MAPK signals in response to growth and stress 
stimuli (367-369).  Post-transcriptionally, Mig6 degradation is likely facilitated by 
microRNA species against Mig6 (e.g., miR148a, which has been implicated in 
controlling insulin biosynthesis) (370, 371), as well as the mRNA-degrading enzymes, as 
the 3’-UTR of Mig6 contains many AU-rich elements (AREs) (372, 373).  Interestingly, 
Mig6 is possibly translated during stress conditions when general protein translation is 
halted.  The ability of Mig6 to avoid translational inhibition is likely because the Mig6 5’-
UTR region bears putative internal ribosomal entry sites (IRES) that allows for atypical 
translation initiation.   
Studies examining the post-translational modifications of Mig6 are emerging.  
Some have suggested that mitogen stimulation triggers Mig6 phosphorylation (at Ser 251, 
Tyr 394, Tyr 395, Tyr 458, and Ser 461 sites), leading to decreased Mig6-EGFR binding 
(374-379).  However, based on the protein sequence alignments, it is more likely that the 
phosphorylation modifications change Mig6 and other proteins’ association patterns.  For 
example, the Ser 251 site of Mig6 is located within the predicted 14-3-3 protein 
association domain, and the Ser 461 site is adjacent to the SH3 binding region.  Perhaps 
the post-translationally modified Mig6 regulates mitogenic signaling cascades via an 
EGFR binding-independent mechanism.   
The clearance of Mig6 protein is controlled by the proteosomal degradation 
systems, as Mig6 is modified by poly-ubiquitin and is subsequently targeted to the 26S 
proteasome (369).  However, the pressing question is whether or not Mig6 is subject to 
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mono-ubiquitinylation.  For example, the mono-ubiquitin tagged Mig6 might tether 
EGFR toward lysosomes, and Mig6 has been shown to haul EGFR toward lysosomes in 
an EGFR ubiquitinylation-independent manner (360).  In addition, Mig6 might bind to 
ubiquitin-associated and SH3 domain-containing protein B (Ubash3b, better known as 
Sts-1).  Sts-1 is known to promote EGFR stabilization by interfering with Cbl-mediated 
down-regulation and degradation of EGFR.  It will be interesting to examine the interplay 
between Mig6, Sts-1, and EGFR, and its relation to controlling EGFR lysosomal 
degradation programs.   
Mig6 controls organ development and tissue homeostasis 
Mig6 is expressed in multiple tissues and organs (e.g., breast, lung, brain, liver, 
uterus, heart, kidney, and pancreas) with a distinctive temporal expression patterns.  For 
example, Mig6 is barely detectable in the livers of the rat fetus; yet its expression 
becomes abundant in the newborn (380).  Mig6 expression level is also elevated in the 
window of metanephric mesenchyme to nephron epithelium conversion during kidney 
development (381).  Finally, Mig6 is differentially expressed in the endometrium in the 
stages of pregnancy.  In fact, the Mig6 expression pattern nicely mirrors the gestational 
estrogen and progesterone expression patterns, suggesting estrogen- and progesterone- 
induced Mig6 likely serves as feedback inhibitor to regulate the maintenance of 
pregnancy (382, 383).    
The critical developmental and physiological roles of Mig6 are demonstrated by 
Mig6 knockout (Mig6-/-) mice.  Mig6-/- mice have 50% embryonic lethality, and the 
surviving Mig6-/- mice were first found to have altered lung architecture (384).  Gradually, 
the mice developed chronic obstructive pulmonary disease, degenerative joint disease, 
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skin hyperplasia, endometrial hyperplasia, and spontaneous tumors in the skin, biliary 
ductal epithelia, mammary gland, and gastric mucosa (385-390).  To further investigate 
the roles of Mig6 in different organs, conditional Mig6 knockout animals were generated.  
Thyroid-specific Mig6 knockout mice displayed altered EGFR membrane distribution in 
the thyrocytes, and developed thyroid tumors (391, 392).  Limb-targeted deletion of Mig6 
resulted in elevated expression of EGFR signaling and progenitor markers (Sox9, notch1, 
beta-catenin, and transforming growth factor beta mediators) in articular chondrocytes, 
enhanced cartilage matrix degradation, and thickened articular cartilage in mice (393).  
Similarly, deficiency of Mig6 in the chondrocytes leads to an osteoarthritis-like disorder, 
due to excessive proliferative activity of the articular cartilage (394).  In the uterine 
epithelium-specific Mig6 knockout mice, Notch1 expression in the epithelial cells is 
increased, which promotes endometrial hyperplasia and the onset of estrogen-dependent 
endometrial tumors (395).   
Mig6 also modulates tissue homeostasis and regeneration in experimental models 
of injury.  For instance, Mig6-/- mice displayed higher hepatocyte proliferation after a 
partial hepatectomy (396).  Likewise, ovariectomized Mig6-/- treated with progesterone 
and estrogen had endometrial hyperplasia and developed endometrial adenocarcinoma.  
Surgical removal of knee ligament and meniscus in Mig6-/- mice leads to rapid and 
increased joint damage (397).  In addition, Mig6-/- mice are susceptible to the formation 
of chemically induced skin tumors (385).  Overall, the published reports define Mig6 as 
an inhibitor of cell proliferation, and Mig6 deficiency in mice results in penetrant 
phenotypes related to hyperproliferation of injured tissue types.  With that being said, 
tissue regeneration and remodeling are extremely complicated processes.  How 
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temporally regulated stress- and cytokine-sensitive Mig6 interplays with mitogenic 
signaling cascades in damaged tissue types remains unknown.  The studies described in 
Chapter 2, 3, and 4 address this critical question. 
Mig6 controls tissue destruction   
Mig6 is induced by in vitro stress stimuli including: lipid agonists, synthetic 
glucocorticoids, hypoxia, Staphylococcus Aureus infection, and mechanical stretch (364, 
398-404).  Because the above reactions are strongly associated with inflammatory 
responses and cell death, it is conceivable that Mig6 might not only inhibit cell 
proliferation, but also promote cell destruction.  Indeed, Mig6 can induce transcriptional 
activation of the master stress mediator nuclear factor κB (NF-κB) by sequestering the 
inhibitor of κB-α (IκB-α) via Mig6’s Cdc42 binding domain (365, 405, 406).  
Additionally, Mig6 has been reported to activate another well-characterized cellular 
stress regulator, c-Jun N-terminal kinase (JNK) (407, 408).  The pro-apoptotic features of 
Mig6 have recently been determined, for example: 1) overerexpression of Mig6 promotes 
non-small cell lung cancer cell apoptosis, whereas Mig6 knockdown prevented cancer 
cell death (409), 2) Mig6 reduces Akt and ERK signaling, and Mig6 is required for 
hypoxia-induced cardiomyocyte death (410), 3) uterine epithelial cells lacking Mig6 have 
higher Baculoviral IAP repeat containing 3 (Birc3, also called inhibitor of apoptosis 
protein 1) expression levels (395), whereas progesterone positive cells lacking Mig6 and 
Phosphatase and tensin homolog deleted from chromosome 10 (PTEN) have higher 
Baculoviral IAP repeat containing 1 (Birc1) levels, and showed significantly decreased 
uterine epithelium cell apoptosis (411), and 4) Mig6 deletion causes impaired apoptosis 
and luminal filling of mouse mammary ducts (390).  
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Chronic pathological stimuli, such as diabetic nephropathy, also induce Mig6 
(407, 412).  But whether such induction is sustainable, and what are the 
pathophysiological consequences of Mig6 elevation under prolonged stress conditions, 
are not known.  From examining developmental biology, Mig6 could possibly attenuate 
mitogenic signaling cascades and facilitate cell differentiation at the final stage of 
stress/injury-induced tissue regeneration/remodeling (380, 381, 413, 414).  Reverse 
evidence comes from cancer biology, where Mig6 has been reported to modulate 
epithelium-to-mesenchyme transition (415).  Apart from a role in facilitating cell 
maturation, Mig6 could be essential in restraining cell expansion in post-injury tissue 
because Mig6 expression levels are elevated during cellular senescence and Mig6 
overexpression leads to pre-mature senescence (416, 417).  The bottom line is, in most 
circumstances, restricting mitotic cell (e.g., epithelial, stromal, and vascular cells) 
expansion is central to tissue homeostasis.  As a proof of concept, Mig6-/- mice exhibited 
accelerated and increased joint fibrosis after ligament and meniscus trauma, and cardiac 
specific Mig6-overexpressing transgenic mice are protected from maladaptive cardiac 
hypertrophy due to decreased tissue inflammation and fibrosis (387, 397, 418).  Finally, 
the most interesting question is, whether or not the post-mitotic cells (e.g., neurons and 
pancreatic beta cells) could benefit from Mig6 modification.  For instance, disruption of 
Mig6 might contribute to protection against cell apoptosis.   
The metabolic roles of Mig6 
Mig6 was initially identified as an insulin-responsive gene in the rat liver (380).  
Ironically, the metabolic roles of Mig6 are largely unknown.  Recently, Ku et al. 
suggested that Mig6 controls cholesterol homeostasis and bile acid synthesis, and mice 
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with Mig6 deficiency specifically in the liver developed hepatomegaly and fatty liver 
(419).  However, the detailed molecular mechanisms are not fully defined.  
Mig6 has been suggested to inhibit pancreatic islet proliferation.  Recently our 
laboratory reported that Mig6 is induced by a synthetic glucocorticoid, dexamethasone; 
and Mig6 is responsible for glucocorticoid-induced beta cell proliferation blockade (420).  
In the work to follow, I will address the roles of Mig6 as a stress-responsive factor in 
mediating beta cell dysfunction and death.  I hypothesized that Mig6 will be induced by 
various diabetogenic stress stimuli; and I predicted that Mig6 would promote beta cell 
death via inhibiting EGFR signaling cascades.  The specific aims of my research are to 
determine if Mig6 is a stress-inducible factor that controls beta cell apoptosis (Chapter 
2), to determine the extent to which Mig6 controls T1D progression in vivo (Chapter 3), 
and to determine if Mig6 attenuates EGFR signaling cascades and facilitates beta cell 
death in the T2D milieu (Chapter 4). 
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2 INDUCIBLE GENE 6 TRIGGERS APOPTOSIS AND EXACERBATES ER 
STRESS-INDUCED BETA CELL DEATH 
2.1 Synopsis 
 
The increased insulin secretory burden placed on pancreatic beta cells during 
obesity and insulin resistance can ultimately lead to beta cell dysfunction and death and 
the development of type 2 diabetes. Mig6 is a cellular stress responsive protein that can 
negatively regulate the duration and intensity of EGFR signaling and has been classically 
viewed as a molecular brake for proliferation.  In this study, we utilized Mig6 
heterozygous knockout mice (Mig6+/-) to study the role of Mig6 in regulating beta cell 
proliferation and survival.  Surprisingly, the proliferation rate of Mig6+/- pancreatic islets 
was lower than wild-type islets despite having comparable beta cell mass and glucose 
tolerance.  We thus speculated that Mig6 regulates cellular death.  Using adenoviral 
vectors to overexpress or knockdown Mig6, we found that caspase 3 activation during 
apoptosis was dependent on the level of Mig6.  Interestingly, Mig6 expression was 
induced during ER stress and its protein levels were maintained throughout ER stress.  
Using polyribosomal profiling, we identified that Mig6 protein translation was 
maintained whereas the global protein translation was inhibited during ER stress.  In 
addition, Mig6 overexpression exacerbated ER stress-induced caspase 3 activation in 
vitro.  In conclusion, Mig6 is transcriptionally up-regulated and resistant to global 
translational inhibition during stressed conditions in beta cells and mediates apoptosis in 
the form of caspase 3 activation.  The sustained production of Mig6 protein exacerbates 
ER stress-induced beta cell death.  Thus, preventing the induction, translation, and/or 
function of Mig6 is warranted for increasing beta cell survival. 
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2.2 Introduction 
T2D is an endemic disease that greatly impacts the healthcare and financial 
systems in both developed and developing countries (421).  T2D is characterized by 
tissue insulin resistance and pancreatic beta cell failure (422).  During the development of 
T2D, insulin resistance is initially compensated for by increased insulin secretion by the 
beta cells and beta cell mass expansion.  However, the body’s insulin demands eventually 
exceed the beta cell secretory capacity thus placing an insurmountable burden on the ER; 
the unmitigated protein synthesis/folding stress in the ER of beta cells finally initiates an 
apoptotic response (423, 424).   
The execution mechanism of ER stress-induced apoptosis remains an area of 
intensive study.  Multiple signaling pathways tightly control a cell’s life and death 
decisions.  Whereas the activation of CHOP and JNK signaling pathways and their direct 
connections to the mitochondrial apoptotic program are considered to be the classical ER 
stress-induced cell death mechanism (425-427), the cross-talk between the ER stress 
responsive factors and canonical cell proliferation and survival signaling pathways is an 
emerging field.  For example, Tribbles homolog 3 (TRIB3), an inhibitor of the Akt 
signaling pathway, was recently found to respond to stress stimuli in beta cells.  The up-
regulation of TRIB3 leads to cell apoptosis by promoting translocation of Bcl-2-
associated X (BAX) to the mitochondria (428-430).  Here, we identified Mig6 as an ER 
stress-responsive protein, which modulates beta cell apoptosis.   
Mig6 was identified as a feedback inhibitor of EGFR signaling (413, 431).  By 
binding to EGFR, Mig6 controls the temporal and spatial continuity of EGFR signaling 
cascades (359, 360, 362).  Interestingly, Mig6 expression is induced by many stress 
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stimuli including hypoxia, osmotic stress, mechanical strain, and LPS-induced infections 
in various cell types (369, 400, 410, 432, 433).  Nevertheless, the role of Mig6 in 
response to ER stress in beta cells has not been investigated.   
ER stress not only initiates adaptive responses by transcriptionally up-regulating 
stress-responsive proteins but also directly controls the protein translation machinery.  
Under normal physiological conditions, cap- and scanning-dependent translation is the 
default translation mechanism.  In contrast, during stressed conditions such as those that 
occur during the development of type 2 diabetes, global protein translation is halted to 
conserve resources and mitigate the unfolded protein stress (434).  Meanwhile, cells 
enhance cap-independent translation to generate proteins that are involved in stress 
alleviation or apoptosis induction.  Intriguingly, Mig6 is resistant to global translation 
inhibition under hypoxic stress in a prostate cancer cell line (435).  Thus, we speculate 
that Mig6 is a stress-responsive molecule that modulates cellular apoptosis in diverse 
disease states including diabetes. 
During our characterization of the proliferation and survival of beta cells from 
mice lacking one Mig6 allele in the present study, we hypothesized that Mig6 is an 
inducer of apoptosis.  In addition, we speculated that Mig6 would be induced during ER 
stress.  Ultimately, we have identified a new role for Mig6 as a mediator of ER stress-
induced apoptosis in pancreatic beta cells.  Thus, Mig6 becomes a potential therapeutic 
target to preserve pancreatic beta cell mass and prevent the irreversible pathogenesis of 
diabetes. 
2.3 Results 
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2.3.1 Mig6 heterozygous knockout mice have similar glucose tolerance and 
pancreatic beta cell area, but decreased islet proliferation 
Previous reports showed that deletion of Mig6 in mice leads to hyperactivation of 
EGFR signaling pathways and the development of tumors in the skin, lungs, gall bladder, 
and bile duct (436, 437).   Mice with both Mig6 alleles nullified also had increased 
embryonic lethality (438), and in our breeding facility we rarely obtain Mig6 homozygote 
knockout mice (3 out of 234 pups; 1.3% observed from heterozygous matings).  We, 
therefore, utilized Mig6+/- and their wild-type control littermates (Mig6+/+) to study the 
function of Mig6 in regulating glucose homeostasis and the proliferation of beta cells in 
vivo.  Methods are described in detail in Chapter 5.  Intraperitoneal glucose tolerance 
tests were performed on 8- to 10-week-old mice following a 5 h fast. Blood glucose 
concentrations in Mig6+/+ and Mig6+/- mice were not different at fasting or throughout the 
glucose tolerance test (Figure 2-1A; all figures for the data chapters are located at the 
end of their respective chapter).  We then harvested the pancreata from the same animals 
to study the islet morphology and beta cell cross-sectional area.  Similarly, Mig6+/+ and 
Mig6+/- showed comparable beta cell cross-sectional area and islet morphology (Figure 
2-1B and 2-1C).  Surprisingly, islet proliferation of Mig6+/- mice was lower than Mig6+/+ 
mice, as measured by the numbers of beta cells positive for phosphorylated histone H3 in 
vivo (Figure 2-1D) and tritiated-thymidine incorporation in isolated islets in vitro 
(Figure 2-1E). 
2.3.2 Mig6 regulates caspase 3-mediated beta cell apoptosis 
Because the regulation of beta cell mass involves the balance between processes 
that both increase and decrease the numbers of beta cells (260), we hypothesized that 
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Mig6+/- mice islets must have decreased apoptosis because they have comparable beta cell 
area and decreased beta cell proliferation.  To study the role of Mig6 in regulating beta 
cell apoptosis, we first employed an adenovirus carrying an shRNA against rat Mig6 
mRNA to knockdown Mig6 in rat insulinoma INS-1-derived 832/13 cells (75% 
knockdown efficiency, Figure 2-6A).  Following the knockdown, cell apoptosis was 
induced by etoposide (a topoisomerase toxin that causes DNA double strands break).  
The activation of cellular apoptosis was measured by the amount of cleaved caspase 3 by 
western blotting (Figure 2-2A and 2-2B), and a caspase 3 activity assay (Figure 2-2C).  
Indeed, knocking down Mig6 protected beta cells from etoposide-induced apoptosis as 
indicated by decreased caspase 3 activity following treatment with etoposide (Fig. 2-2C).  
In addition, adenoviral-mediated overexpression of Mig6 (Figure 2-6B) significantly 
exacerbated etoposide-induced apoptosis (Figure 2-2D and 2-2E).  These results 
suggested that Mig6 regulates caspase 3-mediated beta cell apoptosis.   
2.3.3 Mig6 exacerbates ER stress-induced beta cell death 
As chronic hyperglycemia and hyperlipidemia in diabetes disrupt pancreatic beta 
cell ER homeostasis and lead to beta cell death (439), we further investigated the 
apoptosis-regulating function of Mig6 during ER stress.  To induce ER stress, we utilized 
a pharmacological ER calcium channel blocker thapsigargin to the compromise protein 
folding capacity of the ER.  As hypothesized, overexpression of Mig6 in 832/13 cells 
remarkably exacerbated thapsigargin-induced beta cell apoptosis (Figure 2-3A and 2-
3B).  The phosphorylation of eIF2α and the induced CHOP protein expression served as 
hallmarks of the UPR in an ER stress environment (Figure 2-3A, 2-3C, and 2-3D).  
Interestingly, overexpression of Mig6 did not influence the magnitude and induction of 
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the UPR, suggesting that the apoptosis-promoting mechanism of Mig6 is downstream 
and/or independent of the UPR pathways. 
To verify that caspase 3 cleavage was indicative of apoptosis and ultimately cell 
death, PI staining was performed on cells transduced with control or Mig6-
overexpressing adenoviruses.  As both adenoviruses express GFP, cell death was 
measured in only those cells successfully transduced by adenoviruses (e.g., GFP positive 
cells).  As indicated by PI staining, Mig6 overexpression induced cell death in cells 
treated with DMSO or thapsigargin (Figure 2-3E). 
2.3.4 Mig6 mRNA expression is induced and stabilized by ER stress 
The transcription of Mig6 was induced by ER-stress in a time-dependent manner 
in 832/13 cells (Figure 2-4A), suggesting that Mig6 is a bona fide stress-responsive 
protein (432, 440, 441).  Importantly, Mig6 gene expression was also induced in primary 
rat islets exposed to thapsigargin for 6, 16, and 24 h (Figure 2-4B).  In contrast, the 
mRNA level of pdx-1 was unchanged in thapsigargin-treated 832/13 cells (Figure 2-4A), 
and notably was decreased in thapsigargin-treated rat islets at all time-points studied 
(Figure 2-4B).  Despite the elevated Mig6 mRNA level during ER stress, Mig6 protein 
expression was unchanged (Figure 2-4C and 2-4D).  In contrast, Pdx-1 protein level 
decreased in the stressed environment. 
Mig6 is categorized as an immediate early gene, which are usually induced by p38 
and JNK/stress-activated protein kinases (SAPKs) (442).  We thus investigated the 
participation of three different mitogen-activated protein kinases (MAPKs) in regulating 
Mig6 transcription.  Pharmacological MEK (UO126), p38 (PD169316), or JNK 
(SP600125) inhibitors did not block the thapsigargin-induced Mig6 mRNA expression 
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(Figure 2-7A).  However, the combination of JNK and p38 inhibitors hindered the ER 
stress-stimulated Mig6 expression by 40% (Figure 2-7B). 
Sequence analysis of the Mig6 mRNA reveals putative AREs in the 3’-
untranslated region (443).  ARE-containing mRNAs are translated into proteins that 
normally control cell survival and are usually labile (444).  In response to stimuli, ARE-
containing mRNAs associate with different ARE-binding proteins thus yielding increased 
or decrease stability.  We analyzed the half-life of Mig6 during ER stress using 
actinomycin D (an antibiotic that causes a transcription initiation blockade).  We 
discovered that Mig6 mRNA was stabilized by ER stress (Figure 2-4E).  
2.3.5 Mig6 translation is maintained during ER stress 
During ER stress, general protein biosynthesis is decreased through a phospho-
eIF2α-dependent manner as a protective mechanism to conserve cellular energy and 
prevent protein-folding overload (445).   However, some UPR adapter proteins are 
translated continuously during ER stress.  Most of the alternatively translated mRNAs 
contain upstream open reading frames or IRES (446).  Not surprisingly, the 5’-
untranslated region of Mig6 mRNA is rich in GC content (443), which might form 
secondary structures and possibly serve as an IRES.  To test if Mig6 is alternatively 
translated during ER stress, we employed polyribosome analysis to examine the 
polyribosome association pattern of Mig6 mRNA.  After stimulating 832/13 cells with 
thapsigargin (or DMSO as an unstressed control), sucrose gradient layered-cell lysates 
were fractionated, and the isolated mRNAs from the fractions were analyzed by qRT-
PCR.  Upon thapsigargin treatment, the overall polyribosome level was significantly 
reduced whereas monoribosome levels were robustly elevated (Figure 2-5A).  The Mig6 
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mRNAs distribution in the ribosome profiles showed the same occupancy in control and 
stressed conditions (Figure 2-5B and Table 2-1).  Under normal conditions, 76% of 
Mig6 mRNAs were associated with translating polysomes (which was defined as 
fractions 6 to 10).  During ER stress, 60% of Mig6 mRNA remained associated with 
polysomes (the difference between control and thapsigargin-mediated polysomal 
occupancy was not statistically significant).  In this report, ATF4 served as positive 
control (Figure 2-5C and Table 2-1) because ATF4 mRNA associates with translating 
ribosomes under stress conditions (447).  On the other hand, cylinD1 was used to 
demonstrate general protein translation blockade (448).  The polysome-associated 
cyclinD1 mRNA level shifted from 87% in control group to 57% in ER-stress conditions 
(Figure 2-5D and Table 2-1).  These findings suggested that Mig6 translation was 
maintained, whereas global translation was attenuated during ER stress. 
2.4 Discussion 
The hyperglucolipidemic milieu present during the pathogenesis of diabetes 
compromises the integrity of the ER in pancreatic beta cells.  The perturbed ER 
eventually initiates a series of molecular pathways to trigger cell death.  Our work 
presented here highlights a new mechanism linking ER stress to beta cell apoptosis 
through an adaptor protein, Mig6.  During our characterization of Mig6+/- mice we 
speculated that Mig6 could also be a regulator of beta cell death.  Consequently, we 
demonstrated that Mig6 exacerbates ER stress-induced cell apoptosis.  Interestingly, 
Mig6 transcript was both induced and stabilized by ER stress.  Finally, we showed that 
the translation of Mig6 was preserved during ER stress whereas global protein translation 
was attenuated.   
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Mig6 was initially characterized as an immediate early gene induced by 
glucocorticoids and hormones (443, 449).  More recently, Mig6 was identified as a 
negative regulator of EGFR in multiple tissues (437, 450, 451).  Much of the research 
regarding Mig6 has focused on its role as an anti-proliferative tumor suppressor in 
various tissues (362, 385, 431, 436).  On a molecular level, Mig6 inhibits EGFR 
activation through a two-tiered mechanism:  suppressing EGFR kinase and directing 
EGFR degradation (359).  Correspondingly, a loss of Mig6 is associated with murine and 
human tumorigenesis (385, 436, 452, 453).  Nevertheless, increasing evidence suggests 
that Mig6 responds to diverse pathophysiological stimuli, including mechanical stress, 
tissue injury, and hypoxia (396, 410, 432).  However, the detailed stress-sensing 
mechanism and the consequences of Mig6 induction in different tissues remains to be 
fully characterized.  Our study suggests that Mig6 regulates pancreatic beta cell apoptosis 
during ER stress.  This finding not only provides a new drug target to prevent ER stress-
associated beta cell death in diabetes, but also indicates a possible role of Mig6 as a pro-
apoptotic molecule in treating cancers.   
Because Mig6 is an inhibitor of EGFR, we hypothesized that haploinsufficiency 
of Mig6 would result in increased pancreatic beta cell mass.  However, Mig6+/- mice had 
the same glucose tolerance and beta cell mass compared to Mig6+/+ mice under normal 
chow diet-fed conditions.  Surprisingly, islet proliferation from Mig6+/- mice was lower 
than that in Mig6+/+ mice.  How islets from Mig6+/- mice respond to a challenge that 
requires an expansion of beta cell mass, such as following a partial pancreatectomy or 
during high fat feeding remains to be determined.   
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As beta cell mass is regulated by the balance between cell proliferation and death, 
we speculate that Mig6+/- islets have lower levels of apoptosis.  Conversely, we 
hypothesized that elevated levels of Mig6 could induce cell death.  To address this 
hypothesis, we used the INS-1-derived rat insulinoma cell line 832/13 to identify whether 
or not Mig6 regulates apoptosis.  We observed that whereas Mig6 overexpression 
exacerbated beta cell apoptosis and cell death through caspase 3-mediated pathways, 
silencing Mig6 mitigated apoptosis.  During chemical-induced ER stress, Mig6 
overexpression also led to increased beta cell apoptosis and death.  Our results suggest 
that Mig6 most likely regulates beta cell death during ER stress independent of the 
canonical CHOP-mediated pathway.  Instead, Mig6 possibly compromises traditional 
growth factor receptor-mediated cell survival signals, such as Akt, ERK, and their 
downstream signaling molecules (454, 455).   
Intriguingly, ER stress induced Mig6 mRNA expression, partially through the 
activation of p38 and SAPK pathways.  Being a classical immediate early gene, the Mig6 
mRNA contains AU-rich elements, which are targets for fast degradation (Mig6 t½ = 
34.64 min, see Figure 2-4E).  However, Mig6 mRNAs were, in fact, stabilized under ER 
stress conditions (Mig6 t½ > 120 min, see Figure 2-4E).  Typically, translating mRNAs 
are degraded rapidly during stress conditions.  By clearing the transcription and 
translation load, the ER is freed to correct unfolded/misfolded proteins (456).  For 
example, proinsulin mRNAs are unstable in stressed beta cells (457, 458).  Yet our work 
presented here suggested an enhanced stability of Mig6 mRNA during ER stress.  We 
speculate that beta cells conserve Mig6 transcripts during stress conditions should the 
need to initiate the apoptotic program arise.   
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In adaptation to ER stress, global protein synthesis is inhibited to prevent the 
accumulation of misfolded proteins in the ER lumen.  The profound protein translation 
attenuation is correlated with the activation of PERK and the phosphorylation of 
eukaryotic translation initiation factor 2 alpha (eIF2α).  Phosphorylated eIF2α binds to 
eIF2B, whereby it interferes with the assembly of the translation initiation complex, and 
thus cap-dependent translation initiation stalls (459).  However, the genes essential for 
alleviating the stress or triggering apoptosis escape this translational blockade.  Many of 
the preferentially translated genes contain upstream open reading frames or internal 
ribosomal entry sites in the 5’-untranslated regions, which allows for cap-independent 
translation initiation to occur during cellular stress (447, 460-463). Mig6 should be added 
to the list of genes that evade complete translational blockade during stress as its 5’-
untranslated region has secondary structures that possibly serve as the internal ribosomal 
entry site (449).  From our observation, Mig6 protein level was maintained during ER 
stress, whereas other protein levels were decreased.  The polyribosome analysis in 832/13 
cells revealed that Mig6 mRNAs remained associated with actively translating 
polyribosomes during ER stress.  In agreement with our work, Thomas et al. reported that 
Mig6 mRNAs continue to associate with polyribosomes during hypoxic stress (435).  On 
the other hand, mRNAs of the classically induced ER stress gene ATF4 were shifted from 
untranslating monoribosomes to translating polyribosomes upon ER stress in beta cells.  
In contrast, cyclinD1 mRNAs were redistributed from polyribosomes to monoribosomes 
in the stressed conditions.  Indeed, translation inhibition in the UPR is not limited to 
cyclin D1.  However, the drastic depression of cyclin D1 translation might slow down 
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cell cycle progression, thus permitting beta cells to either re-establish ER homeostasis or 
proceed to apoptosis (464). 
This study demonstrates that Mig6 is a stress-responsive protein mediating beta 
cell death.  Mig6 transcripts are induced, stabilized, and remain translated during ER 
stress.  Additionally, Mig6 regulates beta cell apoptosis through a caspase 3-dependent 
pathway.  Further studies must be undertaken to understand on the molecular level how 
Mig6 bridges growth factor signaling and ER stress-induced apoptosis.  This work 
highlights that Mig6 should be considered as a target for alleviating ER stress and beta 
cell death for the prevention and treatment of diabetes.  
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Figure 2-1   
Mig6+/+ and Mig6+/- mice have same similar glucose tolerance and, islet morphology, 
but different islet proliferation rates.   
Eight- to ten-week-old Mig6+/+ and Mig6+/- mice (n = 6-8 per group) were submitted to 
(A) intraperitoneal glucose tolerance testing and pancreata were assessed for (B) beta cell 
cross-sectional area and (C) islet morphology (insulin: red, glucagon: green, and nuclei: 
blue).  (D) Relative beta cells proliferation rates were determined in vivo by counting 
phospho-histone H3 (green) and insulin (red) stained cells normalized to total islet 
numbers.  (E) Islet proliferation rates were measured in vitro by [3H]-thymidine 
incorporation assays (islets from the same genotype were pooled, n = 3).  *, p < 0.05 
between Mig6+/+ and Mig6+/-. 
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Figure 2-2 
Knockdown of Mig6 attenuates etoposide-induced apoptosis, whereas 
overexpression of Mig6 exacerbates apoptosis.   
INS-1-derived 832/13 cells were transduced with adenoviruses producing either a 
scrambled control RNA (siCon) or a small interfering hairpin RNA sequence against 
Mig6 (siMig6).  After 4 hours of 50 nM etoposide treatment, immunoblotting was 
performed to determine the cleaved caspase 3 levels as an indicator of apoptosis (A, B), 
or cell lysates were used for a caspase 3 activity assay (C).  INS-1 cells were transduced 
with adenoviruses carrying CMV-promoter driven GFP (cmvGFP) or Mig6 (cmvMig6).  
After treating with 50 nM etoposide, cell lysates were collected for immunoblotting (D, 
E).  Data are presented as representative immunoblots and means ± SEM; n = 3-4.  *, p < 
0.05 between etoposide-treated siCon and siMig6; #, p < 0.05 between etoposide-treated 
cmvGFP and cmvMig6. 
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Figure 2-3  
Overexpression of Mig6 exacerbates apoptosis.   
INS-1-derived 832/13 cells were transduced with adenoviruses carrying cmvGFP or 
cmvMig6.  After 48 h, cells were treated with 1 µM thapsigargin for 0, 4, or 6 h.  (A) Cell 
lysates were collected for immunoblotting to determine cleaved caspase 3 (B), 
phosphorylated eIF2α (C), and CHOP (D) levels.  Data are presented as representative 
immunoblots and means ± SEM; n = 3-4.  *, p < 0.05 between cmvGFP and cmvMig6 
groups at both 4 and 6 h thapsigargin treatment.  (E) Cell death was measured by 
propidium iodide (PI) staining in 832/13 cells transduced with adenoviruses carrying 
cmvGFP or cmvMig6 and treated with DMSO or 1 µM thapsigargin for 6 h.  Data 
represent means ± SEM; n = 5.  *, p < 0.05 between cmvGFP and cmvMig6 groups. 
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Figure 2-4 
Thapsigargin-induced Mig6 mRNA expression.   
(A) INS-1-derived 832/13 cells were treated with 1 µM thapsigargin for the indicated 
times.  Isolated mRNA was subjected to qRT-PCR analysis with Mig6 and Pdx-1 primers 
and probes.  (B) Isolated rat islets were treated with 1 µM thapsigargin for the indicated 
times and collected for qRT-PCR analysis.  (C, D) INS-1-derived 832/13 cells were 
treated with 1 µM thapsigargin for 4 and 6 h.  Cell lysates were collected to determine 
Mig6 protein level.  (E) INS-1-derived 832/13 cells were pre-treated with 1 µM 
thapsigargin for 2 h, followed by 5 µg/ml actinomycin D treatment for 0, 20, 40, 60, 120 
min, and subjected to qRT-PCR analysis.  Data are presented as means ± SEM; n = 3-4.  
*, p < 0.05 between the indicated groups. 
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Figure 2-5 
Translation (polyribosome association) of Mig6 is maintained during ER stress.   
(A) INS-1-derived 832/13 cells were treated with DMSO or 1 µM thapsigargin for 6 h.  
Cell lysates were separated on a sucrose gradient.  Ten fractions were collected while 
absorbance at 254 nm was continuously monitored to indicate the 40S ribosome subunits, 
60S ribosome subunits, 80S monosomes and polysomes.   Samples from adjacent 2 
fractions were pooled and subjected to RT-PCR analysis.   Fractions 1-4 represent the 
monosomes, whereas fractions 5-10 represent the polysomes.  Mig6 (B), ATF4 (C), and 
cyclinD1 (D) mRNA in the fractions were presented as percentage of unfractionated 
inputs.  Data are presented as means ± SEM; n = 4. 
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Table 2-1  
Quantitative results of Figure 2-5 B-D. 
Tg, thapsigargin.  Data are presented as means ± SEM; n = 4.  a, p < 0.05 vs. DMSO.       
 
Table 2-1 
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Figure 2-6 
Mig6 expression.   
qRT-PCR analysis of Mig6 knockdown (A) and over-expression efficiency (B).  *, p < 
0.05 between control and Mig6 knockdown or Mig6 overexpressing groups. 
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Figure 2-7 
Mig6 transcription and translation is partially mediated by MAPKs.   
(A) INS-1-derived 832/13 cells were pre-treated with a MEK inhibitor (UO126), p38 
inhibitor (PD169316), or JNK inhibitor (SP600125) at the indicated dose for 1 h, 
followed by 4 h of 1 µM thapsigargin treatment.  Mig6 mRNA was determined by qRT-
PCR.  (B) Indicated inhibitor cocktails were used to pre-treat INS-1-derived 832/13 cells 
for 1 h following 1 µM thapsigargin treatment for 4 h.   Mig6 mRNA was determined by 
qRT-PCR.  Data are presented as means ± SEM; n = 4.  *, p < 0.05 between thapsigargin-
treated and MAPKi-treated groups. 
 
 
 
 
 
 
Portions of the text in this chapter are reproduced from: Chen Y-C, Colvin ES, Maier 
BF, Mirmira RG, Fueger PT. (2013) Mitogen-inducible gene 6 triggers apoptosis and 
exacerbates ER stress-induced β-cell death. Mol Endocrinol. 27(1):162-71. 
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3 MIG6 HAPLOINSUFFICIENCY PROTECTS MICE AGAINST 
STREPTOZOTOCIN-INDUCED DIABETES  
3.1 Synopsis 
EGF and gastrin co-administration is effective in correcting hyperglycemia and 
pancreatic beta cell mass deficiencies in various T1D rodent models, yet the failure in 
clinical translation of this treatment implies that EGF-mediated tissue repair is a 
complicated process warranting further investigation.  In this study, we aimed to 
determine if EGF receptor feedback inhibition by Mig6 limits the effectiveness of EGF, 
and contributes to the development of T1D.  We hypothesized that Mig6 
haploinsufficiency, and hence heightened EGFR signaling, would abrogate the 
development of diabetes in mice.  To this end, we treated Mig6+/- and Mig6+/+ with 
multiple low doses of streptozotocin (STZ) to induce beta cell death and diabetes. 
We found that whereas STZ-treated Mig6+/+ mice became diabetic, STZ-treated Mig6+/- 
mice remained fully glucose tolerant.  Concurrently, STZ-treated Mig6+/- mice exhibited 
preserved levels of circulating insulin following a glucose challenge.  As insulin 
sensitivity was similar between Mig6+/- and Mig6+/+ mice, the preserved glucose 
tolerance in STZ-treated Mig6+/- mice is likely the result of preserved beta cell function.  
Conversely, Mig6 overexpression in isolated islets compromises glucose-stimulated 
insulin secretion.  Studies in 832/13 INS-1 beta cells suggested that Mig6 hinders EGF 
receptor activation, thereby inhibiting EGF-mediated DNA damage repair.  Finally, STZ-
treated Mig6+/- mice have greater beta cell mass recovery at 20 days post-STZ.  These 
data demonstrate that a reduction in Mig6 promotes beta cell damage repair, thus 
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abating the progression of diabetes.  Our work suggests that Mig6 may be a novel 
therapeutic target for beta cell preservation in T1D. 
3.2 Introduction 
T1D is a progressive disease characterized by autoimmune-mediated destruction 
of the insulin-secreting beta cells of the pancreas (31).  To cure T1D, most research 
efforts and clinical trials have focused on understanding and modulating immunological 
responses.  Unfortunately, to date none of the therapies targeting the immune system 
have proven to be efficacious in the long-term (465).  As an alternative to immune 
modulation, cellular therapies promoting the recovery and survival of beta cells could be 
of value for treating T1D (30, 466, 467).  Based on the ”honeymoon phase” (a disease 
remission period often seen in newly diagnosed T1D patients after initiation of insulin 
therapy), human beta cells appear to have finite potential to recover from assaults (90, 
468), and this notion is supported by multiple experimental studies (79, 98, 469).   
Additionally, the beta cell recovery/survival capacity could be enhanced in vivo by 
introducing antioxidant enzymes and trophic factors (470-472).  For example, EGF and 
gastrin treatments have been shown to prevent/reverse the development of diabetes in 
various rodent models (337, 339, 340, 343).  However, the lack of understanding in 
molecular events underlying such effects impedes the clinical translation of EGF as an 
anti-diabetic agent.  In the current study, we aimed to investigate if EGFR is desensitized 
in the T1D milieu by an endogenous EGFR feedback inhibitor; and if such inhibitor 
modulates functional beta cell mass recovery in a model of beta cell destruction. 
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Playing pivotal roles in diverse intracellular programs, EGFR signaling cascade is 
fine-tuned by multiple feedback regulators, including Mig6.  Following EGFR activation 
by ligand binding and dimerization, Mig6 is rapidly induced to: 1) suppress EGFR kinase 
activity, and 2) facilitate EGFR endocytosis and degradation (361, 362, 473, 474).  
Interestingly, Mig6 expression is also induced by physiological stress stimuli, suggesting 
that Mig6 possibly plays crucial roles in integrating stress responses and growth factor 
signaling to maintain tissue homeostasis (454, 475, 476).  If stress persists, however, the 
sustained up-regulation of Mig6 might lead to pathological consequences.  In fact, we 
have shown that glucocorticoids and endoplasmic reticulum stress up-regulate Mig6 in 
the pancreatic beta cells, leading to cell cycle arrest and apoptosis, respectively (420, 
477).  Because beta cell fate dictates the progression to diabetes, it is essential to 
understand if stress-inducible Mig6 counteracts EGFR signaling pathway, leading to beta 
cell dysfunction and destruction in the pathogenesis of diabetes.  In the present study, we 
investigated whether haploinsufficiency of Mig6, hence heightened EGFR signaling, 
protects mice against the development of diabetes.  To this end, we treated wild-type and 
Mig6 heterozygous knockout mice with multiple low doses of streptozotocin to elicit beta 
cell death and an immune response that mimics human T1D in mice and then performed 
metabolic assessment and morphological analyses.  Additionally, we used rat islets and 
832/13 INS-1 derived beta cells to examine the molecular signaling events mediated by 
Mig6 that are associated with beta cell dysfunction and destruction in the T1D milieu.   
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3.3 Results 
3.3.1 Mig6 is induced by proinflammatory cytokines 
Originally characterized as an immediate-early response gene (478), Mig6 is 
induced by various growth factors and cellular stress stimuli to regulate tissue 
homeostasis(363).  We sought to determine whether Mig6 is also induced by T1D-
associated pathological stimuli, henceforth mediating the progression of diabetes.  
Because the proinflammatory cytokines are a major contributor of beta cell dysfunction 
and death in T1D, we treated isolated human islets and rat 832/13 INS-1-derived beta 
cells with a cytokine cocktail containing IL-1β, TNF-α, and IFN-γ.  We observed that 
Mig6 expression is induced in both human islets and rat beta cells (Figure 3-1).  
Interestingly, in human islets, Mig6 and Ins expression level are inversely correlated, 
thereby suggesting Mig6 might control beta cell homeostasis and function. 
To identify the cellular and molecular mechanisms controlled by Mig6 in the 
development of diabetes, we exposed 832/13 beta cells to proinflammatory cytokines to 
induce a condition that mimics the islet inflammation present in developing T1D.  As 
shown in Figure 3-2, we discovered that chronic cytokine treatment blunted EGFR 
phosphorylation/activation in beta cells.  As Mig6 is a bona fide EGFR inhibitor and 
Mig6 expression is induced by proinflammatory cytokines, we speculated that the 
cytokine-induced Mig6 is responsible for the inactivation of EGFR.  Indeed, siRNA-
mediated suppression of Mig6 restores the cytokine-induced attenuation of EGFR and 
ERK1/2 activation.   
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3.3.2 Mig6 haploinsufficiency protects against STZ-induced metabolic dysfunction 
To determine the pathophysiological roles of Mig6 during the development of 
T1D, we challenged Mig6+/- and Mig6+/+ mice with multiple low doses of STZ (MLD-
STZ).   Heterozygous rather than homozygous Mig6 knockout mice were used because: 
1) the homozygous knockouts have been reported to have higher embryonic lethality rate 
(438), and they are not viable in our facility, and 2) under normal conditions, 
heterozygous mice exhibit physiologic and metabolic features similar to wild-type 
mice( 477).  MLD-STZ administration is known to provoke hyperglycemia by: 1) a direct 
DNA-damaging effects in beta cells, and 2) an indirect inflammatory effect that 
facilitates islet dysfunction and death (479).  Hence, we employed MLD-STZ treatment 
as an experimental model to mimic the beta cell destruction in human T1D.  We 
previously demonstrated that Mig6+/- and Mig6+/+ mice exhibit comparable islet 
architecture and glucose tolerance under normal chow-fed conditions (477).  In the 
current study, we treated 10-week-old Mig6+/- and Mig6+/+ mice with MLD-STZ, and 
performed metabolic and histological analyses on various days following STZ treatments 
(Figure 3-3).  Whereas STZ-treated Mig6+/+ mice developed profound glucose 
intolerance, STZ-treated Mig6+/- mice (hereafter referred to as STZ-Mig6+/- mice) 
remained glucose tolerant compared to saline-treated control mice at the time of 
measurement (Figures 3-4).  Additionally, STZ-Mig6+/+ exhibited fasting hyperglycemia 
compared to STZ-Mig6+/- mice (223.4 ± 15.42 vs. 184.0 ± 10.19, p < 0.05).   
Concurrently, STZ-Mig6+/- mice had higher serum insulin concentrations following a 
glucose injection (Figures 3-5).  As Mig6+/- and Mig6+/+ mice treated with or without 
STZ have comparable insulin tolerance, the preserved glucose tolerance in STZ-Mig6+/- 
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mice is likely the result of preserved beta cell function.  In fact, pancreatic islets from 
STZ-Mig6+/- mice have higher Pdx-1 and IRS2 mRNA expression levels comparing to 
islets from STZ-Mig6+/+ mice.  Taken together, these data suggest that Mig6 is required 
for the destructive events leading to glucose intolerance and the loss of islet beta cell 
integrity following STZ treatment. 
 
3.3.3 Mig6 regulates beta cell integrity and function 
The findings above suggest Mig6 participates in the beta cell destruction and/or 
dysfunction in this rodent diabetes model.  To further examine a role for Mig6 in beta cell 
(dys)function, we treated rat islets with an adenoviral vector containing Mig6 and 
demonstrated elevated Mig6 expression significantly reduces glucose-stimulated insulin 
secretion (Figure 3-6).  Additionally, because ERK signaling has been implicated in beta 
cell integrity and function, and Mig6 suppressed EGFR signaling (including 
phosphorylation of ERK), we determined the contribution of Mig6 in suppressing 
downstream effectors of ERK activation.  Elevated Mig6 expression indeed reduced ERK 
target gene expression (e.g., Pdx1 and Ins1).  Collectively, our findings suggest that 
cytokine-induced Mig6 abrogates EGFR and ERK signaling cascades in beta cells, and 
the elevated Mig6 compromises beta cell function. 
 
3.3.4 Mig6 haploinsufficiency does not affect STZ- and cytokine-induced islet 
inflammation  
As mentioned earlier, MLD-STZ treatment provokes glucose intolerance and 
hyperglycemia and mimics human T1D through the activation of islet inflammation.  To 
determine if Mig6 regulates islet inflammation, we examined the degree of immune cell 
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infiltration in STZ-Mig6+/- and Mig6+/+ mice.  As indicated in Figure 3-7, Mig6+/- and 
Mig6+/+ mice showed comparable, low insulitis scores.   Furthermore, islets from Mig6+/- 
and Mig6+/+ mice exhibited similar cytokine-responsiveness, as both produce similar 
amounts of nitric oxide.  Taken together, these data suggest that whereas Mig6 likely 
does not modulate immunity in this model, it is crucial in controlling beta cell function 
and integrity during a diabetogenic assault. 
 
3.3.5 Mig6+/- mice have improved beta cell mass recovery following STZ treatment 
To determine if Mig6 regulates beta cell regeneration following MLD-STZ 
treatment, we examined the histomorphology of isolated Mig6+/- and Mig6+/+ mouse 
pancreata.  Whereas Mig6+/+ exhibited a sustained decrease in insulin-positive cross-
sectional area, beta cell mass recovered by 21 days post-STZ in Mig6+/- mice to a level 
comparable to saline-treated mice (Figure 3-8).  To identify whether the observed 
regeneration occurred by replication, we performed pH3 staining to evaluate the beta cell 
mitosis rate.  Interestingly, STZ-Mig6+/- and Mig6+/+ mice had essentially identical beta 
cell replication rates, suggesting another factor(s) contributes to Mig6 haploinsufficiency-
enhanced beta cell mass recovery.  
 
3.3.6 Mig6 mediates DNA damage-induced beta cell apoptosis 
We speculated that the enhanced recovery of beta cells observed in STZ-Mig6+/- 
mice is due to elevated beta cell survival through enhanced repair/recovery mechanisms.   
We again used 832/13 cells to analyze these cellular events.  First, we observed that 
diabetogenic factors such as proinflammatory cytokines (Figure 3-9) and reactive oxygen 
species (data not shown) induce beta cell DNA damage/repair, as indicated by the Ser-15 
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phosphorylation and accumulation of p53 protein, the hallmarks of activated DNA and 
cellular repair.  Next, we examined if a reduction in Mig6 would heighten EGFR 
signaling and promote beta cell survival.  Importantly, siRNA-mediated suppression of 
Mig6 in 832/13 cells elevated camptothecin-induced p53 protein expression, and partially 
protected beta cells from DNA-damage induced apoptosis, as measured by caspase 3 
cleavage. 
3.4 Discussion 
T1D is caused by the autoimmune destruction of insulin-secreting beta cells.  To 
date, the only cures for T1D are pancreas or islet transplantation, which require long-term 
immunosuppression.  Despite their successes, these cures are profoundly hindered by the 
availability of suitable cadaveric organs and islets for transplantation.  Given these 
limitations, novel therapeutic approaches aimed at promoting beta cell regeneration 
and/or survival to combat the autoimmune attack are necessary for patients with T1D.  
Several groups have utilized EGF and gastrin co-administration to increase beta cell mass 
and reverse hyperglycemia in various T1D animal models (87, 337, 339, 340, 343, 480).  
Unfortunately, this approach has failed in clinical translation, suggesting that the 
downstream signaling of ligand-mediated receptor activation is complicated and warrants 
further investigation. 
We and others (335) have become interested in the anti-diabetogenic effects of 
EGFR signaling, and specifically for our work, the impact of the EGFR feedback 
inhibitor Mig6.  In current study, by employing Mig6 happloinsufficient mice, we 
exposed this anti-diabetic capacity of EGFR signaling.  Mig6 limits EGFR signaling by 
blocking receptor dimerization and promoting its degradation, leading to anti-mitogenic 
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effects (361, 362, 390).  Interestingly, recent studies have demonstrated that Mig6 
transcription is induced by stress stimuli (363), and Mig6 regulates cellular apoptosis to 
maintain tissue homeostasis during development and in pathological conditions (390, 454, 
481).  These aspects of Mig6’s biology compelled us to determine if Mig6 limits the 
therapeutic potential of EGF, facilitates beta cell death, and promotes the progression to 
diabetes.   
By employing Mig6 happloinsufficient mice, we were able to examine the roles 
of Mig6 in the progression of T1D.  We treated Mig6+/- and Mig6+/+ mice with multiple 
low doses of STZ to induce diabetes.  We observed that Mig6+/- mice are resistant to 
developing STZ-induced diabetes, as they have preserved post-prandial glycemia as well 
as glucose tolerance and serum insulin levels following a glucose load.  The insulin 
sensitivities (before and after STZ treatment) are comparable between Mig6+/- and 
Mig6+/+ mice, suggesting that the improved glucose homeostasis in STZ-Mig6+/- mice is 
likely the result of preserved beta cell function.  Nevertheless, we recognize that the 
systemic Mig6 haploinsufficiency might alter immunity, angiogenesis, or nutrient 
utilization in other tissues.  However, we established that Mig6 modulates beta cell 
function and integrity in vivo and in vitro.  Whereas half of the beta cells in Mig6+/- and 
Mig6+/+ were ablated by the STZ treatment, the remaining islets from Mig6+/- mice have 
higher Pdx-1 and IRS2 expression levels.  In contrast, elevated Mig6 expression 
compromises glucose-stimulated insulin secretion in isolated rat islets.  As Mig6 has been 
shown to inhibit ERK1/2 activation in beta cells (420), we examined other beta cell genes 
that are transcriptionally regulated by ERK1/2 in the context of adenovirally-mediated 
Mig6 overexpression.  We found that Pdx-1 and Ins1/2 mRNA levels are reduced in 
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832/13 INS-1 cells with elevated Mig6 expression.  Of exceptional importance, Mig6 
possibly compromises beta cell function in T1D humans, as we demonstrated that 
proinflammatory cytokine-induced Mig6 mRNA expression is inversely correlated with 
preinsulin mRNA levels in isolated human islets.  
We utilized 832/13 cells to study the consequences of Mig6 induction in relation 
to EGFR signaling in a T1D milieu.  We established, for the first time, that 
proinflammatory cytokines impair EGF-induced EGFR activation.  Excitingly, siRNA-
mediated suppression of Mig6 partially restored the cytokine-mediated attenuation of 
EGFR activation.  Because proinflammatory cytokines promote nitric oxide (NO) 
production and cause beta cell damage (100), it will be interesting to ultimately determine 
if NO is the mediator of EGFR unresponsiveness as implicated in other cell types (482-
484).  In addition, it remains to be determined if cytokine-induced NO participates in the 
induction of negative regulators of EGFR such as Mig6.  Regardless, our discovery 
brings a new level of complexity to traditional growth factor-based anti-diabetic therapies.  
We suggest that in pathological conditions, intracellular and extracellular stress can 
directly inactivate mitogenic signaling pathways via stress-inducible negative regulators.  
Particularly, we propose that before employing growth factors as anti-diabetic therapies 
or in regenerative medicine, cellular stress should be eliminated.  Excitingly, a recent 
study from Wang et al. presented the same concept (343).  They reported that a 
combinatorial therapy of anti-CD3/CD8 immunotherapy (to eradicate inflammatory 
assaults) and gastrin/EGF (to augment beta cell regeneration) reverses late-stage diabetes 
in NOD mice.   
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Previous reports have suggested that EGF/gastrin co-treatment increases beta cell 
mass via promoting beta cell proliferation (339, 343), transdifferentiation(87, 340, 480), 
and neogenesis (343).  In the current study, we used Mig6+/- mice as an alternative model 
to examine the beta cell regeneration mechanisms regulated by EGF.  We showed that 
STZ-Mig6+/- mice had improved beta cell mass recovery at 20 days following STZ 
treatment.  However, beta cell replication is not likely the mechanism for increasing beta 
cell mass, as Mig6+/- and Mig6+/+ mice exhibited similar STZ-stimulated beta cell 
proliferation rates.  Given this, we infer that the recovery of insulin-positive area is 
attributed to other sources such as transdifferentiation or restoring of insulin positivity 
(e.g., beta cell recovery) (79).  However, we do not consider the duct-to-beta cell 
transdifferentiation the main contributor of increased beta cell mass in STZ-Mig6+/- mice, 
because CK19/Ins positive cells are extremely rare at the time points where our 
histological studies were performed (data not shown).   
As an alternative to the above mechanisms, we were compelled to examine if 
Mig6 haploinsufficiency facilitates beta cell survival because: 1) newly generated beta 
cells are more susceptible to cell death (485), 2) we and others have demonstrated that 
Mig6 promotes cell apoptosis (481, 486), and 3) EGFR has been associated with 
promoting DNA damage repair and facilitating cell survival in various cell types (487, 
488).  We revealed that proinflammatory cytokines induce DNA damage in 832/13 cells, 
as indicated by elevated levels of phosphorylated- and total p53 protein.  In addition, we 
identified that siRNA-mediated suppression of Mig6 partially protected beta cells from 
DNA damage-induced apoptosis, associated with elevated p53 expression levels.  
However, we cannot rule out the possibility that Mig6 mediates beta cell death through 
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EGFR-independent mechanisms as suggested by Hopkins et al. (390).  Further, EGFR 
facilitates cell survival through various molecular actions, such as promoting PI3K/Akt- 
and Ras/ERK-mediated transcription of DNA repair genes( 489, 490), and activating 
nuclear proteins involved in damage repair (491, 492).  Thus, future investigations should 
elucidate through which signaling pathways Mig6 regulates EGFR activity and cell 
survival.   
Taken together, we demonstrated that whereas Mig6 deficiency does not enhance 
STZ-stimulated beta cell proliferation, it likely allows the beta cell to mount a more 
robust damage-repair response, leading to superior recovery of beta cells and insulin 
positivity.  Our discovery highlights the largely overlooked beta cell repair mechanisms 
as potential therapeutic targets for T1D (466).  Indeed, accumulated cadaveric studies 
reported that eleven long-term T1D patients have minimal levels of c-peptide and 
preserved beta cells (albeit degranulated and scattered as small clusters) (29, 102, 493), 
and human islets are capable of recovering from attacks (468, 469, 494, 495).  These 
findings point out that patients with T1D certainly have beta cells that could likely be 
repaired if provided the proper stimulation.  We suggest that targeted inhibition of Mig6 
could be of value in treating T1D, as we have shown that Mig6 compromises beta cell 
functional integrity and facilitates beta cell death. 
In summary, our data demonstrated that cytokine-induced Mig6 negatively 
controls EGFR signaling activation, compromises beta cell function and identity, and 
inhibits recovery of beta cells in a chemically-induced form of T1D.  This study indicates 
that using growth factors alone as anti-diabetogenic therapies might be ineffective, as 
pathological stimuli can directly turn-off mitogenic signaling pathways via negative 
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regulators such as Mig6.  Further, we propose that targeting the beta cell recovery 
machinery may represent a promising therapeutic strategy to prevent or reverse the 
progression of T1D.   
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Figure 3-1 
Proinflammatory cytokines induce Mig6 expression.  
Human islets (A) or 832/13 cells (B) were treated with cytokines, and Mig6 expression 
was determined by qRT-PCR analysis.  Mig6 mRNA levels are reported as fold induction 
relative to non-cytokine-treated samples.  Data are means ± SEM; n = 4.  *, p < 0.05).  
(C) Preinsulin mRNA levels in human islets (± cytokines) were plotted against Mig6 
mRNA levels (r = −0.64, p < 0.05). 
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Figure 3-2 
Mig6 suppression rescues cytokine-inhibited EGFR activation.   
(A) 832/13 cells were pretreated with cytokines for 16 h, starved for 2 h, and stimulated 
with 10 ng/ml recombinant rat EGF for 5 min.  Cell lysates were collected for western 
blot analysis to determine p-EGFR, EGFR, and tubulin levels.  (B) Quantified p-EGFR 
protein levels are shown.  Data are reported as fold induction relative to non-cytokine, 
non-EGF-treated group.  n = 3.  *, p < 0.05 non-treated vs. EGF-treated; #, p < 0.05 non-
cytokine EGF-stimulated vs. cytokine EGF-stimulated.  The solid line indicates cropped 
lanes within the same experiment.  (C) 832/13 cells are transduced with adenoviral 
vectors carrying either a scrambled control RNA (siCon) or shRNA sequence against 
Mig6 (siMig6).  Mig6 knockdown efficiency was determined by qRT-PCR.  n = 3.  *, p < 
0.05.  (D) Following transduction, cells are treated with cytokines and EGF as described 
above.  Protein levels of p-EGFR, EGFR, p-ERK, ERK, and tubulin were determined by 
western blot analysis.  (E-F) Quantified p-EGFR and p-ERK protein levels are shown.  
Data are reported as fold induction related to cytokine-treated, non-EGF-stimulated group. 
n = 3.  *, p < 0.05 non-treated vs. EGF-treated; #, p < 0.05 siCon EGF-stimulated vs. 
siMig6 EGF-stimulated.
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Figure 3-3 
Schematic representation of the experimental timeline.  
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Figure 3-4 
Mig6+/- mice are protected from STZ-induced glucose intolerance.  
(A) Glucose tolerance testing was performed at day 3 post-STZ injection (B) Time course 
data as well as area-under-the-curve (AUC) are reported.  n = 5.  *, p < 0.05.
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Figure 3-5 
STZ-Mig6+/- mice have preserved beta cell function.   
(A-B) Circulating insulin levels during a glucose challenge, also presented as (B) area-
under-the-curve.  n = 8.  *, p < 0.05.  (C-D) Blood glucose levels during insulin tolerance 
test pre- and post-STZ treatment.  (E-G) mRNA levels of Pdx-1, IRS2, and Preinsulin in 
islets isolated from saline-injected Mig6+/+, STZ-treated Mig6+/-, and STZ- treated 
Mig6+/+ mice.  Target gene expression levels were determined by qRT-PCR and 
standardized to the saline-injected (dotted line) group.  n > 5.  *, p < 0.05. 
 	   101	  
 
 
Figure 3-6 
Overexpression of Mig6 compromises beta cell integrity and islet function.  
(A-C) 832/13 cells were either not transduced or transduced with adenoviral vectors 
carrying cmvGFP or cmvMig6.  Pdx-1, IRS2, and Ins1/2 mRNA levels were determined 
by qRT-PCR and are reported as fold differences relative to non-transduced samples.  n = 
5.  *, p < 0.05.  (D) Isolated rat islets were transduced with adenoviral vectors carrying 
cmvGFP or cmvMig6, and then glucose-stimulated insulin secretion (GSIS) was assessed. 
n = 3.  *, p < 0.05 low vs. high glucose; #, p < 0.05 high glucose stimulated-cmvGFP vs. 
cmvMig6). 
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Figure 3-7 
Mig6 dose not modulate cytokine- or STZ-induced immune response.   
(A-B) Insulitis scoring (defined in Methods) of STZ-Mig6+/- and -Mig6+/+ mouse 
pancreas.  Shown are representative images of islets and quantified results (white, 0; light 
gray, 1; dark gray, 2; black, 3).  (C) Islets from Mig6+/- (white bars) and Mig6+/+ (black 
bars) were treated with cytokines and nitric oxide levels in the islet culture were 
measured.  n = 3.  *, p < 0.05 vs. non-treated.   
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Figure 3-8 
STZ-Mig6+/- mice have enhanced beta cell mass recovery.   
(A-B) Beta cell area was measured and expressed relative to pancreas area.  The dotted 
line indicates beta cell area of non-STZ treated mice.  n = 8.  *, p < 0.05 vs. STZ-Mig6+/+.  
(C-D) The percentage of beta cells positive for pH3 were quantified in saline controls 
(white bars) and at 3 and 20 days post-STZ (gray and black bars, respectively).  Arrows 
indicate proliferating beta cells.  n > 5.  *, p < 0.05 vs. non-STZ.  Representative images 
are shown in A and C.
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Figure 3-9 
Mig6 promotes DNA damage-induced beta cell death.  
(A) 832/13 cells were treated with adriamycin for 6 h or cytokines for the indicated times.  
p-p53, p53, and tubulin protein levels were determined.  (B-D) 832/13 cells were 
transduced with siCon or siMig6 adenoviral vectors, and treated with vehicle (white bars) 
or 1 µM camptothecin (CA; black bars).  p-p53, p53, caspase-3, and Gapdh protein levels 
were determined.  n = 3.  *, p < 0.05 vs. non-treated; †, p < 0.05 vs. siCon + CA. 
 
 
 
 
 
 
 
Portions of the text in this chapter have been reproduced from: Chen Y-C, Colvin ES, 
Griffin KE, Maier BF, Fueger PT. (2014) Mig6 haploinsufficiency protects mice against 
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4 GLUCOLIPOTOXICITY-INDUCED MIG6 DESENSITIZES EGFR 
SIGNALING AND PROMOTES PANCREATIC BETA CELL DEATH 
4.1 Synopsis  
 RTK signaling cascades have been considered the primary promoters of beta cell 
mass preservation and expansion.  Interestingly, the distal effectors of RTKs are typically 
inhibited under diabetogenic stress conditions.  Therefore, we hypothesized that RTKs 
are inhibited in the diabetic milieu, which then leads to decreased downstream signaling 
of RTKs and beta cell loss.  To this end, we investigated a well-characterized RTK, 
EGFR, in beta cells during GLT.  We discovered that the activation of EGFR is inhibited 
by stress stimuli present in T2D (e.g., GLT and ER stress).  Moreover, we demonstrated 
that the stress-inducible EGFR negative regulator Mig6 is a major contributor to EGFR 
inhibition during GLT.  Mig6 primarily controls EGFR, but not other RTKs signaling 
cascades, in the pancreatic beta cells.  In addition, Mig6 mediates beta cell survival and 
death.  Because Mig6 overexpression facilitates JNK activation, it also exacerbates GLT-
induced beta cell apoptosis.  Conversely, silencing Mig6 enhances expression of the pro-
survival factor Birc5 in GLT-treated beta cells.  Importantly, we discovered that Mig6 is 
elevated in human islets from T2D donors.  In summary, we established that T2D and 
GLT induce Mig6 in pancreatic beta cells.  The elevated Mig6 desensitizes EGFR 
signaling and exacerbates beta cell death.  Our findings suggest that Mig6 could be a 
novel therapeutic target for T2D, as blocking Mig6 could possibly enhance mitogenic 
signaling cascades in a diabetic milieu to promote beta cell survival and prevent beta cell 
death. 
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4.2 Introduction 
 To ensure proper, robust insulin release, beta cell insulin secretion capacity (e.g., 
beta cell function) and insulin stores (dependent on beta cell mass) are tightly regulated.  
For example, during pregnancy and obesity, functional beta cell mass is increased to 
allow for optimal glycemic control.  Studies have suggested that the growth factor 
receptor signaling pathways, such as EGFR and insulin like growth factor 1 receptor 
signaling cascades are primary contributors of beta cell mass expansion.  On the contrary, 
persistent hyperglycemia and hyperlipidemia (glucotoxicity and lipotoxicity, hereafter 
jointly referred as GLT) accentuate beta cell failure.  Interestingly, the activation of 
proximal signaling molecules of growth factor receptors (e.g., Akt and Glycogen 
synthase kinase 3/GSK3) is inhibited under stress conditions (455, 496, 497).  Such 
observations prompted us to speculate whether the activation of the growth factor 
receptors themselves are inhibited in the pathological states.  In other words, we 
hypothesized that the diabetogenic stress stimuli repress the activation of beta cell surface 
receptors, thereby leading to the reduced activation of proximal signaling molecules of 
the receptors, and contributing to beta cell loss.  
 In this work, we primarily focused on how dampened EGFR signaling cascades 
contribute to beta cell loss in a diabetic milieu because EGFR signaling is central to 
preserving beta cells in vivo and in vitro.  Mice carrying pancreatic specific dominant-
active EGFR alleles are protected against the development of beta cell toxin-induced 
diabetes, in that their beta cell apoptosis is inhibited (498).  Conversely, blocking EGFR 
downstream Raf-1 signaling via a pharmacological inhibitor induces beta cell death (499).  
It is crucial to note that EGFR has to remain excitable to help maintain beta cell 
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homeostasis, because mice bearing an inactive form of EGFR in the pancreas failed to 
acquire compensatory beta cell expansion during pregnancy and obesity (336, 500).  
Interestingly, we have established (see Chapter 3) that pro-inflammatory cytokines 
inhibit the activation of EGFR via a stress-inducible EGFR inhibitor, Mig6 (501).  We 
speculated that metabolic stress stimuli could alter EGFR activity via Mig6.  Additionally, 
because Mig6 has been implicated as a regulator of beta cell proliferation and death (420, 
481), we examined the beta cell pro-survival/pro-apoptosis signaling pathways modulated 
by Mig6 in a T2D milieu. 
4.3 Results 
4.3.1 GLT and ER stress attenuates EGFR activation in pancreatic beta cells 
 To study if GLT compromises EGFR activation, we pre-exposed 832/13 INS-1 
cells to medium containing high glucose and palmitic acid and investigated the activation 
of EGFR.  We found that GLT treatment prevents EGF-mediated EGFR phosphorylation 
(Figure 4-1A and 4-1B).   Notably, the total cellular abundance of EGFR is not changed 
by GLT (Figure 4-1C), indicating that the attenuated EGFR phosphorylation and 
activation are likely the consequences of EGFR kinase interruption.  Because GLT 
imposes ER stress on beta cells and triggers deleterious effects such as beta cell death 
(Figure 4-1D and 4-1E), we examined whether the induction of ER stress is sufficient to 
attenuate EGFR activation.  We found that pretreatment with thapsigargin (a 
pharmacological ER stress inducer) significantly inhibits EGFR activation in 832/13 cells 
(Figure 4-1F and 4-1G).  The above findings suggest that the pathological stress stimuli 
present in T2D compromise the activation of EGFR. 
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4.3.2 EGFR feedback inhibitor Mig6 is elevated in GLT-treated rat beta cells and 
T2D human islets 
 To identify the factors associated with EGFR inactivation during GLT, we 
examined a set of well-defined, inducible EGFR inhibitors (502).  We discovered that 
Mig6, an adaptor protein that blocks EGFR activation, is induced by T2D and GLT in 
human and rodents islets, respectively (Figure 4-2).  To further study the specific effects 
of glucotoxicity and lipotoxicity on the induction of Mig6, we treated the 832/13 cells 
with high levels of glucose and/or palmitic acids and measured Mig6 expression levels 
(Figure 4-3A to 4-3E).  We established that high glucose induced Mig6 in both a dose- 
and time-dependent manner (Figure 4-3B and 4-3C).  However, palmitic acid alone did 
not induce Mig6 (Figure 4-3D and 4-3E).  In addition, because high glucose stimulates 
insulin secretion in the beta cells, we speculated that the autocrine or paracrine effects of 
insulin could promote Mig6 expression.  However, exogenous insulin treatment did not 
alter Mig6 expression levels (Figure 4-3F).  These data suggested that diabetogenic 
stress, especially glucotoxicity, induces Mig6 in beta cells. 
4.3.3 GLT-attenuated EGFR activation is rescued by siMig6 
 Because GLT hinders EGFR activation and the inhibitor of EGFR, Mig6, is 
induced by GLT, it is intuitive to speculate that stress-inducible Mig6 controls EGFR 
inactivation during GLT.  Thus, we used a RNA interference approach to examine the 
functional significance of Mig6 during GLT (Figure 4-4).  After silencing Mig6, GLT-
attenuated EGFR and ERK signaling cascades are restored (50% restoration vs. BSA/ 
EGF-treated, Figure 1A), implying Mig6 facilitates GLT-induced EGFR inactivation.   
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4.3.4 Elevated Mig6 facilitates GLT-mediated beta cell death 
 Previously, we demonstrated that Mig6 not only exacerbates ER stress-mediated 
beta cell death, but also inhibits insulin secretion in isolated rodent islets (481, 501).  
Hence, we sought to determine if Mig6 controls beta cell fate during GLT.  In particular, 
because it has been reported that Mig6 facilitates stress activated protein kinase/c-Jun N-
terminal kinase (SAPK/JNK) activation (475), and JNK is a critical mediator of GLT-
induced beta cell death (Figure 4-5A and 4-5B), we investigated if Mig6 promotes JNK 
activation and induces GLT-mediated beta cell death.  We found that in the 
overabundance of Mig6, JNK and caspase 3 are markedly activated at 4 h post-GLT 
treatment; whereas control GFP-overexpressed samples showed the activated JNK and 
caspase 3 at 8 h post-GLT treatment (Figure 4-5C and 4-5E).  Therefore, we concluded 
that Mig6 overexpression aggravated GLT-induced JNK activation and expedited beta 
cell death.  Conversely, knockdown of Mig6 partially prevented JNK phosphorylation 
and activation during GLT (Figure 4-5F).  However, limiting the expression of Mig6 
alone is not sufficient to inhibit GLT-mediated beta cell apoptosis (Figure 4-5G). 
4.3.5 Mig6 controls EGF- but not IGF1- nor HGF-mediated pro-survival signaling 
pathways 
 Mig6 not only modulates pro-apoptotic signaling cascades, but also controls 
multiple growth factor receptors, thereby mediating multiple pro-survival signaling 
pathways.  Based on the information from sequence alignments and structural studies, 
Mig6 likely regulates several RTKs.   First, we established that Mig6 is a bona fide 
EGFR inhibitor in pancreatic beta cells (Figure 4-6A to 4-6C).  Next, we examined if 
Mig6 modulated HGF signaling because HGF is essential in compensatory beta cell mass 
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expansion (503-505), since Mig6 has been implicated in regulating HGF-mediated 
neurite outgrowth (359).  However, our data suggested that Mig6 does not influence HGF 
mitogenic signaling in beta cells (Figure 4-6D and 4-6E).  In addition, we demonstrated 
that Mig6 does not alter IGF-1 signaling in beta cells (Figure 4-6F and 4-6G).   These 
findings indicate that Mig6 modulates RTKs in a cell context-specific fashion; and Mig6 
primarily regulates EGFR signaling in pancreatic beta cells. 
 Finally, we examined if Mig6 modulates pro-survival factors downstream of 
EGFR signaling pathways during GLT.  We identified that a family member of the 
inhibitor of apoptosis (IAP),  5, is a target of Mig6 regulation.  We report that silencing 
Mig6 significantly elevated Birc5 levels in GLT-treated beta cells (Figure 4-6H). 
4.4 Discussion 
Although genetic manipulation of pancreatic EGFR in mice leads to the 
acceleration or prevention of diabetes, the natural history of EGFR kinase activity in 
different phases during the progression of diabetes remain unknown (305, 336, 498, 500).  
In regards to the beta cell destruction phase prior to the onset of diabetes, the extent to 
which diabetogenic stress stimuli alter EGFR activity and impact beta cell life/death 
decisions is unclear.  It has been reported that diabetic stressors could compromise the 
activation and propagation of RTK signaling cascades in pancreatic beta cells (356, 357).  
For example, GLT and cytokine challenges hinder the activation of insulin receptor and 
downstream PI3K, hence prevent the cytoprotective effects of insulin in beta cells (496, 
497, 506).    However, the molecular mechanisms responsible for this stress-mediated 
RTK inactivation remain to be defined.  It is likely that there are stress-responsive factors 
that crosstalk with RTK signaling machinery in pathological conditions.   
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 In this study, we established that glucolipotoxicity and ER stress attenuate EGFR 
activation in pancreatic beta cells via the stress-responsive EGFR inhibitor, Mig6.  Mig6 
was initially characterized as an endogenous EGFR feedback inhibitor but has also been 
suggested to impair other RTKs.  After mitogen stimulation, Mig6 is activated to abolish 
EGFR signaling transmission via a two-tiered mechanism: 1) Mig6 binds to the EGFR 
intracellular kinase domain and inhibits kinase dimerization and activation, and 2) Mig6 
facilitates EGFR endo-lysosomal sorting and degradation.  However, the role of Mig6 as 
a stress-induced modulator has only been revealed recently.  Makkinje at el. first reported 
that mechanical stress in diabetic nephropathy is sufficient to induce Mig6; and the 
transient expression of Mig6 results in selective activation of JNK (475).  Later, Mabuchi 
et al. further suggested that Mig6 is able to bind to IκB-α, resulting in NF-κB activation 
(406).  Recently, Hopkins et al. demonstrated that ligand deprivation promotes Mig6-
mediated c-Abl activation and cell death (390).  Furthermore, as described in the previous 
chapters, we identified that ER stress and pro-inflammatory cytokines both induce Mig6; 
and haploinsuficiency of Mig6 prevents mice from developing an experimentally-induced 
form of T1D (481, 501).   
 Here, we established that Mig6 overexpression facilitates GLT-induced JNK 
activation and beta cell apoptosis.  Conversely, silencing Mig6 promotes the expression 
of an EGFR downstream pro-survival molecule Birc5 during GLT.  Deleterious Mig6-
mediated effects could be EGFR independent or dependent.  Mig6 activates pro-apoptotic 
JNK via its Cdc42/Rac interactive binding domain, representing an EGFR independent 
response (407).  On the other hand, Mig6-promoted Birc5 is transcriptionally and post-
translationally regulated by EGFR signaling cascades.  However, 60% knockdown of 
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Mig6 in 832/13 cells did not prevent GLT-induced beta cell apoptosis.  One possible 
reason could be that Mig6 controls a particular type of cell death.  As we have found that 
the suppression of Mig6 prevents DNA damage-, but not ER stress- and GLT-induced 
beta cell death.  Alternatively, the existence of functionally redundant proteins may 
compensate for the effects of Mig6 deficiency.  There are likely other stress-mediated 
factors controlling EGFR inactivation.  For instance, cell surface EGFR could be 
modified and inhibited by advanced-glycation precursors present in GLT; and cellular 
stress-activated phosphatases could also inactivate EGFR (345, 346, 349).  Lastly, we 
performed our cell death studies using transformed cells, which may have different cell 
death kinetics compared to post-mitotic islet beta cells.  The physiological levels of GLT 
in vivo could create more prolonged assaults in long-lived primary beta cells.  Therefore, 
silencing Mig6 (thus enhancing EGFR signaling) in vivo might better promote beta cell 
damage-repair, given that the primary beta cells are given a longer time to remediate the 
stress.   Prospective studies of our laboratory include the generation of beta cell-specific 
Mig6 knockout mouse model and functional characterization of Mig6 in the experimental 
forms of T2D. 
 This work presented a possible rationalization for defective beta cell proliferation 
and survival observed in the state of chronic over-nutrition.  It is known that short-term 
intralipid infusion enhances beta cell proliferation via EGFR and mTOR signaling 
pathways in adult rodents (314), but chronic nutrient overload (e.g., high-fat diet feeding) 
does not promote beta cell mass expansion (315).  As Mig6 is elevated in islets derived 
from T2D patients, we speculated that Mig6 perhaps contributes to the dampening of 
EGFR signaling activation during the progression of T2D.   
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In summary, we discovered that GLT attenuates EGFR activation via Mig6; and 
Mig6 modulates GLT-induced beta cell apoptosis machinery.  We propose that Mig6 
might be a suitable therapeutic target to foster beta cell proliferation and survival in 
preventing and treating T2D.      
 	   114	  
 
 
 
 
Figure 4-1 
 
GLT and ER stress desensitize the EGFR signaling pathway in pancreatic beta cells. 
(A, B) 832/13 cells were treated with 5 mM glucose and BSA, or 25 mM glucose and 400 
µM palmitic acid (glucolipotoxicity, GLT) for 8 h, followed by a starvation in 5 mM 
glucose medium for 2 h, then stimulated with recombinant rat EGF (rrEGF) 10 ng/ml for 
5 min.  Protein levels of p-EGFR, EGFR, and tubulin were analyzed by western blotting.  
Data are reported as fold induction related to BSA non-stimulated samples.  (C-E) 832/13 
cells were treated with GLT at the times and concentrations as indicated.  Protein levels 
of p-EGFR, EGFR, p-JNK, JNK, p-eIF2α, eIF2α, gapdh, tubulin, and cleaved caspase 3 
were analyzed by immunoblotting.  (C) 832/13 cells were treated with DMSO or 1 µM 
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thapsigargin (Tg, a pharmacological ER stress inducer) for 4 h, followed by starvation 
and rrEGF stimulation.  Protein levels of p-EGFR, EGFR, and tubulin were analyzed by 
western blotting.  All blots are the representative of n ≥ 3 experiments.  *, p < 0.05 vs. 
BSA non-stimulated; #, p < 0.05 vs. BSA EGF-stimulated. 
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Figure 4-2 
 
Mig6 is induced in T2D human and GLT-treated rat islets. 
(A) Isolated human islets from healthy individuals or patients with T2D were collected.  
Mig6 mRNA levels were determined by qRT-PCR (n = 4;  *, p < 0.05).  (B, C) Isolated 
rat islets were treated with BSA, 400 µM palmitic acid (lipotoxicity, LT), 25 mM glucose 
(glucotoxicity, GT), or both (GLT) for 48 h.  Mig6 mRNA levels were determined by 
qRT-PCR.  Mig6, p-eIF2α, eIF2α, cleaved caspase 3, and tubulin protein levels were 
determined by immunoblotting.  n = 4.  *, p < 0.05 vs. BSA. 
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Figure 4-3 
 
Mig6 is induced by glucose but not insulin nor palmitic acid. 
832/13 cells were treated with (A) GLT for the indicated times, (B) 5, 10, 15, 20, or 25 
mM glucose for 4 h, (C) 25 mM glucose or 5 mM glucose + 20 mM mannitol (as an 
osmotic stress control) for 0, 2, 4, or 6 h, (D) BSA, 100, 200, 400 µM palmitic acid for 4 
h, (E) 400 µM palmitic acid for the indicated times, or (F) 0, 10, 100, or 1000 nM 
recombinant human insulin for 4 h.  Mig6 mRNA levels were determined by qRT-PCR.  
n ≥ 3 experiments.  *, p < 0.05 vs. BSA + 5 mM glucose + 20 mM mannitol. 
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Figure 4-4 
 
Down-regulation of Mig6 partially corrects GLT-induced desensitization of the 
EGFR signaling pathway. 
 (A) 832/13 cells are transduced with adenoviral vectors carrying either a scrambled 
control siRNA (siCon) or shRNA sequence against Mig6 (siMig6).  Mig6 mRNA levels 
were determined by qRT-PCR (n = 4; *, p < 0.05).  (B-D) Transduced cells were treated 
with GLT and EGF as described.  Protein levels of p-EGFR, EGFR, p-ERK, ERK, and 
tubulin were determined by immunoblotting.  Data are reported as fold induction related 
to the GLT-treated, non-EGF-stimulated group.  n ≥ 3.  *, p < 0.05 vs. EGF-treated; #, p < 
0.05 vs. siCon EGF-stimulated. 
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Figure 4-5 
 
Mig6 facilitates GLT-induced apoptosis by potentiating JNK activation. 
(A-B) 832/13 cells were pre-treated with 10 µM SP600125 (JNK inhibitor) or DMSO for 
2 h, following GLT treatment for 0 or 4 h.  p-c-Jun, tubulin, cleaved caspase 3 protein 
levels were determined by western blotting.  n = 3 experiments.  *, p < 0.05 vs. GLT.  (C-
E) 832/13 cells were transduced with adenoviruses carrying cmvGFP vs. cmvMig6.  Post 
transduction, cells were treated with GLT for 0, 2, 4, or 8 h.  p-JNK, JNK, cleaved 
caspase 3, and tubulin protein levels were analyzed by western blotting.  (F-G) 832/13 
cells were transduced with adenoviruses carrying siCon vs. siMig6.  Post transduction, 
cells were treated with GLT for 0, 2, 4, or 8 h.  p-JNK, JNK, p-Akt, Akt, cleaved caspase 
3, and tubulin protein levels were analyzed by western blotting.  n = 5.  *, p < 0.05 vs. 
siCon. 
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Figure 4-6 
 
Mig6 control EGF but not IGF1 or HGF pro-survival signaling pathways. 
(A-C) 832/13 cells were transduced with adenoviruses carrying cmvGFP vs. cmvMig6 or 
siCon vs. siMig6.  Post transduction, cells were starved in 5 mM glucose and 0.1% BSA 
medium for 2 h, followed by 10 ng/ml recombinant rat EGF stimulation for 5 min.  (D, 
E) After adenoviral transduction and starvation as in A & B, 832/13 cells were treated 
with 10 nM recombinant human IGF-1 for 10 min.  (F, G) After adenoviral transduction 
and starvation as in A & B, 832/13 cells were treated with recombinant human HGF for 5 
min.  Protein levels of p-EGFR, p-ERK, ERK, p-Akt, Akt, and tubulin were analyzed by 
western blotting.  n ≥ 3.  *, p < 0.05 vs. stimulated;  #, p < 0.05 vs. cmvMig6 EGF-
stimulated.  (H) 832/13 cells were transduced with adenoviruses carrying siCon vs. 
siMig6.  Post transduction, cells were treated with GLT for 0, 2, 4, or 8 h.  Birc5 mRNA 
levels were determined by qRT-PCR.  n = 3.  *, p < 0.05 
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5 MATERIALS AND METHODS 
5.1 Animal studies 
5.1.1 Animals and streptozotocin treatments 
All animals were maintained and used according to protocols approved by the 
Indiana University School of Medicine Institutional Animal Care and Use Committee. 
C57Bl/6J mice lacking one Mig6 allele (Mig6+/−) were obtained from Dr. Vande Woude, 
bred with wild type C57Bl/6J mice (Mig6+/+), and genotyped as previously described 
(438).  Extract-N-Amp tissue PCR kit (Sigma-Aldrich) was used for genotyping.  Mice 
were kept in a standard light-dark cycle with free access to water and a standard rodent 
chow diet. 
For streptozotocin (STZ) treatments, ten-week-old male wild type C57Bl/6J mice 
were intraperitoneally injected with 35 mg/kg body weight or 55 mg/kg body weight STZ 
(Sigma-Aldrich) for five consecutive days.  A separate group of animals was injected in 
the same manner with vehicle (saline) as a control.  Glucose tolerance tests (see below for 
details) were performed 3 days post STZ injection (Table 5-1 and Figure 5-1).  We 
selected the dosage of 35 mg/kg body weight for injecting Mig6+/− and Mig6+/+ mice. 
5.1.2 Metabolic studies 
Glucose tolerance test 
For glucose tolerance testing (GTT), 1.5 g/kg body weight D-glucose (Sigma-
Aldrich) was injected intraperitoneally into 5 h-fasted control or STZ-treated mice.  
Blood was sampled from a tail vain at the indicated time points, and blood glucose was 
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measured using an AlphaTRAK glucometer (Abbott Laboratories).  Serum insulin was 
assayed with an ultra-sensitive mouse insulin ELISA kit (Crystal Chem). 
Insulin tolerance test 
For insulin tolerance testing (ITT), 0.75 U/kg body weight recombinant insulin 
(Eli Lilly & Co.) was injected intraperitoneally into 5 h-fasted pre- and post-STZ treated 
mice.  Blood glucose was determined at the indicated time points. 
5.1.3 Histological studies  
Immunostaining of pancreatic sections was performed as described previously 
(481).  In brief, mouse pancreatic sections (5 µM) were deparaffinized with xylene, and 
rehydrated through a series of graded ethanol solutions.  Afterward, antigen retrieval was 
performed by microwaving slides with Antigen Unmasking Solution (Vector Labs) 
followed by blocking (Serum Free Blocking Reagent, Dako) for 30 min.   
Immunohistochemistry staining 
For immunohistochemistry staining, slides were incubated with guinea pig anti-
insulin antibody overnight at 4°C (all antibodies used are listed in Table 5-2).  The next 
day, immunodetection was performed with a peroxidase conjugated anti-rabbit IgG 
antibody (ImmPRESS, Dako) and peroxidase substrate (VECTOR NovaRED, Vector 
Labs).  Finally, slides were counterstained with hematoxylin and mounted.  Digital 
images were acquired using an Axio-Observer Z1 inverted microscope (Zeiss) equipped 
with an AxioCam color camera.  The area of the insulin-positive cells (calculated using 
Axio-Vision Software) was divided by the total pancreatic area to obtain the beta cell 
cross-sectional area as a percentage of total pancreatic area.  
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Insulitis scoring 
Insulitis scoring was performed by grading islets as follows: 0, no infiltration; 1, 
mild peri-insular mononuclear infiltration; 2, moderate (25–50%) infiltration; 3, massive 
(>50%) infiltration (503).   
Immunoflurescence staining 
For immunoflurescence staining, slides were incubated with anti-insulin, anti-
glucagon, and anti-phospho-histone H3 overnight at 4°C followed by incubation with 
Alexa Fluor 488 or Alexa Fluor 555-conjugated secondary antibodies for 1 h at room 
temperature.  Cells were counterstained with DAPI to visualize the nuclei and then 
imaged using an Axio-Observer Z1 inverted fluorescent microscope (Zeiss), equipped 
with an Orca ER CCD camera (Hammamatsu).  
5.1.4 Islet experiments 
Human islet experiments 
Cadaveric human islets were obtained from Beta-Pro, LLC, the National Disease 
Research Interchange, or the Integrated Islet Distribution Program.  Islets from 4 donors 
with T2D and 4 donors without diabetes were analyzed to determine MIG6 expression 
levels.  A separate set of islets from four healthy donors was treated with a pro-
inflammatory cytokine cocktail (50 U/ml interleukin-1β, 1000U/ml tumor necrosis 
factor-α, and 1000U/ml interferon-γ; Prospec Ltd.) or phospho buffered saline vehicle for 
24 h in DMEM containing 5.5 mM glucose.   
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Rodent islet experiments 
Primary pancreatic islets were also collected from male Wistar rats weighing 
approximately 250 g (507, 508) or collected from Mig6+/+ or Mig6+/- mice.  After 
collagenase digestion, islets were hand-picked and cultured in 5 mM glucose RPMI 
medium (supplemented with 10% fetal bovin serum, 50 units/ml penicillin, and 50 µg/ml 
streptomycin) overnight before drug treatments.  For the virus transduction experiments, 
rat islets were transduced with adenoviral vectors expressing Mig6 or green fluorescent 
protein (GFP) under the control of the cytomegalovirus (CMV) promoter, immediately 
after isolation. 
Glucose-stimulated insulin secretion assay 
Glucose-stimulated insulin secretion assays were performed 48 h post- adenoviral 
vector transduction as previously described (509).  Insulin content in the buffer was 
determined by insulin radioimmunoassay (Coat-A-Count Insulin RIA; Siemens Medical 
Solutions), and data were expressed relative to total islet protein concentration.  
[3H]-thymidine incorporation assay 
Islet proliferation was assessed by measuring the incorporation of [3H]methyl-
thymidine into genomic DNA (510).  [3H]methyl-thymidine was added to groups of 100 
islets at a final concentration of 1 µCi/ml medium for 16 h.  Groups of 30 islets were 
picked in triplicate and washed twice with PBS.  The DNA was precipitated in 500 µl of 
cold 10% tricholoroacetic acid and solubilized by the addition of 80 µl of 0.3 N NaOH.  
The amount of [3H]thymidine incorporated into DNA was measured by liquid 
scintillation counting and normalized by total cellular protein. 
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Nitrite assay 
Groups of 50 islets from Mig6+/+ or Mig6+/- mice were cultured in 100 µl RPMI 
medium or RPMI medium containing the cytokine cocktail for 24 h.  Supernatants were 
removed to measure nitrate/nitrite concentrations as an index of nitric oxide with the 
Griess assay (Promega) according to the manufacturer’s protocol (511). 
5.2 Cell experiments 
INS-1-derived 832/13 rat insulinoma cells were cultured as described (512).   A 
starvation medium (RPMI 1640 containing 2.5 mM glucose and 0.1% BSA) was used for 
EGF stimulation experiments.  Gene overexpression and knockdown were performed as 
previously described (481).  
5.2.1 Apoptosis assays 
To induce apoptosis, cells were treated with 50 nM etoposide (BioVision) for 4 h, 
1 µM thapsigargin (Sigma) for 6 h, or 1 µM adriamycin or camptothecin (BioVision Inc.) 
for 6 h.  Cells were then lysed with RIPA buffer (Santa Cruz).  Caspase 3 enzyme activity 
in the cell lysate was determined using a Caspase 3 Fluorometric Substrate Assay 
(Upstate) and a SpectraMax M5 microplate reader (Molecular Devices).  Protein 
concentration was measured using the BCA Protein Assay kit (Pierce) to normalize 
caspase 3 activity. 
5.2.2 Pharmacological inhibitors  
Inhibition of MAPK pathways by pharmacological agents was achieved via pre-
treating 832/13 cells with 10 µM of the MEK inhibitor UO126, the p38 inhibitor 
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PD169316, or the JNK inhibitor SP600125 (Sigma) for 1 h.  Cells were then treated with 
thapsigargin.  
5.2.3 EGF and cyctokines treatments  
For cytokine plus EGF stimulation experiments, 832/13 cells were pretreated with 
cytokines for 6 h, starved for 2 h, and treated with 10 ng/ml rat recombinant EGF (R&D 
Systems) for 5 min.  
5.2.4 Glucolipotoxicity experiments 
 Palmitic acid-BSA complex solution was prepared according to the literature 
(513).  In brief, sodium palmitate was first dissolved in 0.1 M NaOH buffer at 70°C.  
Next, the palmitic acid solution was mixed with 5% fatty acid-free bovine serum albumin 
(BSA) solution at 37°C to yield a 5 mM palmitic acid-BSA complex stock solution (the 
molecular ratio of fatty acid to BSA was 6: 1).  The resulted clear palmitic acid-BSA 
complex solution and BSA control solution were store at -20 °C. 
 For lipotoxicity experiments, palmitic acid-BSA complex was diluted into serum 
free RPMI culture medium to obtain various concentrations of palmitic acid ranging from 
0.1 mM to 0.4 mM.  Equal volumes of BSA solution were used as carrier controls.   
 For glucotoxicity experiments, 25 mM glucose serum free RPMI culture medium 
supplemented with 0.1% BSA was used as high glucose treatment, and 5 mM glucose 
plus 20 mM D-mannitol (osmotic control) was used as low glucose control.    
 For glucolipotoxicity experiments, 0.4 mM palmitic acid plus 25 mM glucose 
medium was used to create glucolipotoxicity; and BSA plus 5 mM glucose medium was 
used as control. 
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5.2.5 Immunoblot analysis  
Cells were lysed in 1% IGEPAL reagent supplemented with 10% glycerol 
(Sigma), 16 mM NaCl (Sigma), 25 mM 4-(2-hydroxyethyl)-1-piperazineethanesulfonic 
acid (HEPES, Sigma), 60 mM n-octylglucoside (Research Products International Corp.), 
phosphatase inhibitor cocktails (PhosSTOP tablets, Roche) and phosphatase inhibitor 
cocktails (EDTA-free cOmplete tablets, Roche).  Lysates were resolved on a 10% 
NuPAGE Bis-Tris Gel (Invitrogen), transferred to an Immobilon-FL Transfer Membrane 
(Millipore), and incubated with antibodies (all antibodies used are listed in Table 5-3). 
Subsequently, membranes were incubated with IRDye 800 or 700 fluorophore-labeled 
secondary antibodies from LI-COR.  Protein bands were visualized using the Odyssey 
System (LI-COR) and quantified with Image J software (NIH).  
The phosphorylated protein levels presented in bar graphs were normalized by 
total protein levels, and the total (e.g., non-phosphorylated) protein levels were 
normalized to tubulin or GAPDH protein levels.   
5.2.6 Quantitative RT-PCR analysis 
RNA from 832/13 cells, mouse, rat, and human islets was isolated using RNeasy 
Mini or Micro kits (Qiagen).  Reverse transcription was completed with a High Capacity 
cDNA Reverse Transcription kit (Applied Biosystems).  The threshold cycle 
methodology was used to calculate the relative quantities of the mRNA products of Mig6, 
Pdx-1, Ins1/2, NeuroD, IRS2 (TaqMan assays; Applied Biosystems), and pre-insulin 
(SYBR Green methodology; primer sequences were described previously (514)).  PCR 
reactions were performed in triplicate for each sample from at least three independent 
experiments and were normalized to Gapdh or beta-actin gene expression levels. 
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5.2.7 Polyribosome analysis 
Polyribosome analysis was performed as described previously (59, 460).  Briefly, 
832/13 cells were cultured with or without 1 µM thapsigargin for 6 h. 10 minutes prior to 
harvesting, cells were treated with 50 µg/ml cycloheximide to block translation (Sigma). 
Cells were washed and lysed in a buffer of 20 mM pH 7.5 Tris-HCl, 100 mM NaCl, 5 
mM MgCl2, and 0.4% NP-40 supplemented with 50 µg/ml cycloheximide.  Cell lysates 
were homogenized by passing through a 25-gauge needle and incubated on ice for 10 
minutes.  The cell lysate was pre-cleared by centrifugation (9000 × g for 10 minutes at 
4°C) and transferred onto a 10–50% sucrose gradient solution made with the above lysis 
buffer.  A portion of unfractionated lysate was saved and used as the “input” to determine 
steady-state mRNA levels of Mig6, ATF4, and cyclinD1.  The gradients were then 
centrifuged in a Beckman SW-41Ti rotor for 2 h at 35,000rpm at 4°C.  10 gradients were 
fractionated using a Biocomp Gradient Station and collected by a Fraction Collector 
(Bio-Rad).  Meanwhile, absorbance of RNA at 254 nm was recorded using an ECONO 
UV Monitor (Bio-Rad).  RNA was isolated as described above using the RNeasy Mini 
Kit (Qiagen) from each fraction.  The samples from two adjacent fractions were pooled, 
and subjected to qRT-PCR analysis to determine Mig6, ATF4, and cyclinD1 transcripts 
levels. 
5.3 Statistical analysis 
All data are reported as means ± SEM.  Protein and mRNA data were normalized to 
control conditions and were presented as relative expression.  Student's t-test, Pearson 
correlation, or ANOVA (with Bonferroni post-hoc tests) were performed using GraphPad 
Prism software to detect statistical differences (p < 0.05).  
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Table 5-1  
 
Different diabetogenic responses to moderate doses of streptozotocin. 
Ten-week-old male wild type C57Bl/6J mice were intraperitoneally injected with 35 
mg/kg body weight or 55 mg/kg body weight STZ for five consecutive days (n = 3 each 
group).  A separate group of animals was injected in the same manner with saline as a 
control (n = 4).  Glucose tolerance tests were performed at 3 days post STZ injection. 
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Figure 5-1 
 
Different diabetogenic responses to moderate doses of streptozotocin. 
Above figure was generated from data presented in Table 5-1. 
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Table 5-2  
 
List of antibodies used for immunostaining. 
Name Vendor, lot number Dilution  
Anti-glucagon Sigma, #G2654 1: 1000 
Anti-insulin Invitrogen, #180067 1: 250 
Anti-phospho-histone H3 Millipore, #06-570 1: 1000 
Alexa Fluor-conjugated antibodies Invitrogen 1: 1000 
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Table 5-3 
 
List of antibodies used for immunoblotting. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Name Vendor, lot number Dilution  
Anti-Actin MP Biomedicals, #691002 1: 5000 
Anti-Akt Cell Signaling, #2920 1: 1000 
Anti-caspase 3 Cell Signaling, #9662 1: 1000 
Anti-CHOP Santa Cruz, #7351 1: 250 
Anti-EGFR Sigma-Aldrich, #E3138 1: 1000 
Anti-eIF2α Cell Signaling, #5324 1: 1000 
Anti-ERK1/2 Cell Signaling, #4696 1: 1000 
Anti-γ-tubulin Sigma-Aldrich, #T6557 1: 5000 
Anti-Gapdh Abcam, #Ab9483 1: 5000 
Anti-Mig6 Santa Cruz, #D-1 1: 250 
Anti-p53 Cell Signaling, #2524 1: 1000 
Anti-Pdx1 Millipore, #07-696 1: 2000 
Anti-phospho-Akt Cell Signaling, #4056 1: 1000 
Anti-phospho-EGFR Cell Signaling, #3777 1: 1250 
Anti-phospho-eIF2α Cell Signaling, #3398 1: 1000 
Anti-phospho-ERK1/2 Cell Signaling, #4370 1: 2000 
Anti-phospho-p53 Abcam, #Ab1431 1: 1250 
IRDye 800 or 700 fluorophore-
conjugated antibodies 
LI-COR 1: 10000 
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6 DISCUSSION 
6.1 Summary of the current studies  
 The loss of functional beta cells is the final and irreversible step towards the 
development of frank diabetes.  To prevent or cure diabetes, many factors have been 
identified to preserve beta cells.  Among them, growth factors have been considered as 
premier candidates for such an approach because growth factors facilitate cell cycle 
progression and inhibit the mitochondrial apoptotic machinery.  However, the activation 
of growth factor signaling cascades are usually attenuated by chronic pathological stress 
conditions via unknown mechanisms.    
 In this document, I have suggested that the negative regulator of EGFR, Mig6, 
plays an important role in controlling beta cell fate.  Previously, our group discovered 
that Mig6 is induced by synthetic glucocorticoids, and Mig6 contributes to 
glucocorticoid-mediated beta cell cycle arrest (420).  We extended this work by 
examining the roles of Mig6 in regulating beta cell proliferation in vivo, and 
unexpectedly discovered that Mig6 also controls beta cell death (Chapter 2).  We first 
established that Mig6+/- and Mig6+/+ mice have normal glucose clearance and comparable 
beta cell mass.  Yet, we found that beta cells of Mig6+/- mice (bearing enhanced EGFR 
activity) surprisingly have lower proliferation rates compared to Mig6+/+ mice.  Because 
steady-state beta cell mass is controlled by the rates of beta cell proliferation and cell 
death, the decreased beta cell proliferation observed in Mig6+/- mice could be a secondary 
effect of decreased beta cell death.  In other words, we speculated that the beta cells of 
Mig6+/+ mice are not required to proliferate as much because they have lower rate of 
death, which is sufficient for maintaining adequate beta cell mass and glucose 
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homeostasis.  We then tested our hypothesis and examined the molecular events initially 
using 832/13 INS-1 derived beta cells.   We found that Mig6 controls DNA-damage 
induced beta cell apoptosis; and overexpression of Mig6 exacerbates ER stress-induced 
cell death.  Another significant aspect of this study is that we discovered that Mig6 is 
induced by stress stimuli.  Furthermore, we found that Mig6 belongs to a group of 
specialized molecules that are resistant to stress, as Mig6 mRNA is more stable, and is 
preferentially translated under stress.  The roles of stress-inducible Mig6 in diabetes were 
described in Chapter 3 and Chapter 4.   
 We examined the roles of Mig6 in the T1D milieu because previous animal 
studies have demonstrated that EGFR is essential in preventing and reversing T1D.  Yet, 
the EGF-related therapies failed to achieve long-term effects in humans, indicating that 
EGFR signaling pathways are complicated and warrant further investigation.  In Chapter 
3, we discovered that EGFR activation is attenuated by pro-inflammatory cytokines via 
Mig6.  Notably, we reported that Mig6 mediates the progression of T1D, as Mig6+/- mice 
are protected from developing experimentally-induced hyperglycemia and diabetes.  This 
study highlighted the significance of stress-inducible negative regulators in blocking 
growth factor signaling pathways in a diabetic milieu.  Based on this work, we propose 
that the diabetic stress stimuli should be eliminated to allow for maximal efficacy of 
growth factor therapy. 
 In the last data chapter (Chapter 4), we described how Mig6 controls beta cell 
fate in T2D.  We demonstrated that Mig6 is a contributor of EGFR inactivation during 
ER stress and GLT; and that Mig6 controls the activation of beta cell survival signaling 
cascades.  The broader implication of this work is that Mig6 may be a factor limiting beta 
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cell mass expansion in states of nutrient excess because EGFR and mTOR signaling 
pathways have been shown to regulate acute lipid infusion-induced beta cell mass 
expansion in adult rodents.  Yet, chronic dietary nutrient oversupply failed to do so.  
Therefore, we think that the prolonged diabetogenic assaults could activate inducible 
negative regulators (e.g., MIG6 is elevated in T2D islets), which inhibit beta cell 
regeneration and survival.  Our future studies will reveal how Mig6 and other stress-
inducible factors modulate growth factor receptor signal transduction cascades during the 
development of T2D.  
6.2 Future studies  
The previous chapters defined Mig6 as regulator of beta cell proliferation and 
apoptosis.  However, how Mig6 protein is dynamically regulated in (patho)physiological 
settings remains unclear.  For example, whereas various stress stimuli induces Mig6 
mRNA expression, Mig6 protein expression levels often remain unchanged.  We 
suspected that Mig6 is being transported with EGFR toward the endo-lysosomal 
degradation system; and Mig6 protein turnover rates are possibly altered following 
mitogen and stress stimuli.  Alternatively, we considered that it is the qualitative but not 
quantitative features of Mig6 regulating beta cell fates.  For instance, Mig6 could be post-
translationally modified or differentially distributed within the cell to facilitate its binding 
to different molecules.  It is important to determine whether Mig6 and EGFR association 
patterns are changed under different circumstances.  Future studies focusing on 
characterizing Mig6 functional domains and post-translational modification patterns will 
greatly assist the identification of anti-diabetic drug targets against Mig6. 
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 The physiological roles of Mig6 in beta cells require further investigations.  So far, 
we have demonstrated that Mig6+/- whole body heterozygote knockout mice are protected 
from STZ-induced diabetes, most likely because they have preserved beta cell function 
and enhanced beta cell mass recovery.  However, we are aware that the global disruption 
of Mig6 could modify the pancreatic progenitor/vasculature/immune cell repertoires.  
Therefore, we plan to generate Mig6 conditional knockout mice to examine the tissue-
specific effects of Mig6.   Additionally, the roles of Mig6 in human beta cells need to be 
explored.  With the advancement at cell engineering technology, it is feasible to study the 
functional significance of Mig6 in iPS/hESC-derived beta cells (515, 516).  Besides, the 
recently-developed adult human beta cell line could serve as an additional platform to 
examine the extent to which Mig6 controls human beta cell proliferation, senescence, and 
death (517).   
 We have demonstrated that Mig6 attenuates EGFR activity under stressful 
conditions in vitro.   Yet, EGFR activity during the progression of diabetes is not known.  
The temporal examination of: 1) systemic/pancreatic EGF family ligands/receptors 
expression levels, 2) EGF cellular uptake efficiency, and 3) EGF ligands ectodomain 
shedding process (518), will facilitate the identification of remedial windows to promote 
EGF-related therapies.  Plausibly, the shedding products of transmembrane proteins (e.g., 
growth factor precursors/receptors, cytokine/cytokine receptors, and adhesion molecules) 
could serve as early biomarkers to detect or monitor diabetes.   
 The early detection and early treatment are critical in the battle against diabetes 
because once hyperglycemia and other systemic distress are established, it becomes very 
difficult to stop and reverse diabetes.  For instance, the growth factor therapies failed to 
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resurrect beta cells and reverse full-blown diabetes because the beta cell 
intrinsic/extrinsic environments have posed barriers against the activation of growth 
factor signaling cascades.  Excitingly, we have identified Mig6 as a modulator of these 
processes.  Future studies exploring other inhibitors are warranted.  In particular, we 
suggest that the signaling pathways activated by the acute pathological stimuli (e.g., 
short-term cytokine and palmitic acid treatments) are the best candidates to be 
investigated because beta cells usually respond to acute stress stimuli by activating 
compensatory growth and insulin secretion mechanisms (91, 269, 315, 519).  However, 
these pathways are dysregulated with prolonged stress exposure.   It will be significant to 
find the molecular switches of these processes to benefit the identification of therapeutic 
targets to foster beta cell proliferation/survival signaling cascades in adverse conditions.  
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  Poster: Mitogen-inducible gene 6 potentiates glucolipotoxicity-induced  
  pancreatic beta cell death. 
 2012 Center of Diabetes Research, Indiana University School of Medicine 
  Talk: The role of Mitogen-inducible gene 6 in pancreatic beta cell   
  destruction 
 2012 University of Indianapolis 
   Lecture: Diabetes therapy targeting pancreatic beta cells 
 2011 The Midwest Islet Club 5th Annual Meeting 
   Poster: Induction of Mitogen-inducible gene 6 during endoplasmic  
   reticulum stress exacerbates beta cell apoptosis 
 2011 71st Scientific Session American Diabetes Association 
   Poster: Transcriptional regulation of Mig-6 by PPARγ in beta cells 
 2011 The Midwest Islet Club 4th Annual Meeting  
   Talk: Transcriptional regulation of Mig-6 by PPARγ in beta cells 
 
 
Volunteer Experience 
 
 2010 to 2014  Activity Assistant of Molecular Medicine in Action (MMIA) 
   - Assisted with preparing hands-on histological staining workshops 
   for high school students and teachers. 
 2011 to 2013  Student Ambassador of Indiana University School of Medicine  
    graduate program campus recruits 
   - Presented current research to the prospective students, and  
   assisted with recruiting events. 
 
 
Licensure 
 
 Medical Laboratory Scientist License, Taiwan 
 
